6 | body weight | SD | male | 180.4 | g | naive control condition | 84760 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 207.4 | g | naive control condition | 84761 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 225.6 | g | naive control condition | 84762 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 242.6 | g | naive control condition | 84763 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 257.3 | g | naive control condition | 84764 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 182.3 | g | acetaminophen (250 mg/kg) (for 1 days) | 84765 | acetaminophen (250 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | male | 211 | g | acetaminophen (250 mg/kg) (for 8 days) | 84766 | acetaminophen (250 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | male | 227.7 | g | acetaminophen (250 mg/kg) (for 15 days) | 84767 | acetaminophen (250 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | male | 244 | g | acetaminophen (250 mg/kg) (for 22 days) | 84768 | acetaminophen (250 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | male | 258.5 | g | acetaminophen (250 mg/kg) (for 28 days) | 84769 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | male | 181.7 | g | acetaminophen (500 mg/kg) (for 1 days) | 84770 | acetaminophen (500 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | male | 209.3 | g | acetaminophen (500 mg/kg) (for 8 days) | 84771 | acetaminophen (500 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | male | 229.6 | g | acetaminophen (500 mg/kg) (for 15 days) | 84772 | acetaminophen (500 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | male | 241.1 | g | acetaminophen (500 mg/kg) (for 22 days) | 84773 | acetaminophen (500 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | male | 256.6 | g | acetaminophen (500 mg/kg) (for 28 days) | 84774 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | male | 182.4 | g | acetaminophen (1000 mg/kg) (for 1 days) | 84775 | acetaminophen (1000 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | male | 211.6 | g | acetaminophen (1000 mg/kg) (for 8 days) | 84776 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | male | 229.6 | g | acetaminophen (1000 mg/kg) (for 15 days) | 84777 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | male | 246.8 | g | acetaminophen (1000 mg/kg) (for 22 days) | 84778 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | male | 262.4 | g | acetaminophen (1000 mg/kg) (for 28 days) | 84779 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | male | 184.1 | g | naive control condition | 84781 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 205.4 | g | naive control condition | 84782 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 228 | g | naive control condition | 84784 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 246.1 | g | naive control condition | 84786 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 255.5 | g | naive control condition | 84788 | naive control condition | | | | | | | | |

6 | body weight | SD | male | 190.7 | g | acetaminophen (1000 mg/kg) (for 1 days) | 84789 | acetaminophen (1000 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | male | 208.8 | g | acetaminophen (1000 mg/kg) (for 8 days) | 84790 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | male | 231.9 | g | acetaminophen (1000 mg/kg) (for 15 days) | 84791 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | male | 252.7 | g | acetaminophen (1000 mg/kg) (for 22 days) | 84792 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | male | 264 | g | acetaminophen (1000 mg/kg) (for 28 days) | 84793 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | female | 136.2 | g | naive control condition | 84794 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 148.3 | g | naive control condition | 84795 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 156.6 | g | naive control condition | 84796 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 167 | g | naive control condition | 84797 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 172.8 | g | naive control condition | 84798 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 136.3 | g | acetaminophen (250 mg/kg) (for 1 days) | 84799 | acetaminophen (250 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | female | 152.8 | g | acetaminophen (250 mg/kg) (for 8 days) | 84800 | acetaminophen (250 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | female | 161.2 | g | acetaminophen (250 mg/kg) (for 15 days) | 84801 | acetaminophen (250 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | female | 170 | g | acetaminophen (250 mg/kg) (for 22 days) | 84802 | acetaminophen (250 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | female | 175.3 | g | acetaminophen (250 mg/kg) (for 28 days) | 84803 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | female | 134.7 | g | acetaminophen (500 mg/kg) (for 1 days) | 84804 | acetaminophen (500 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | female | 147.9 | g | acetaminophen (500 mg/kg) (for 8 days) | 84805 | acetaminophen (500 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | female | 151.9 | g | acetaminophen (500 mg/kg) (for 15 days) | 84806 | acetaminophen (500 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | female | 157.7 | g | acetaminophen (500 mg/kg) (for 22 days) | 84807 | acetaminophen (500 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | female | 162.5 | g | acetaminophen (500 mg/kg) (for 28 days) | 84808 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | female | 134.2 | g | acetaminophen (1000 mg/kg) (for 1 days) | 84809 | acetaminophen (1000 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | female | 147 | g | acetaminophen (1000 mg/kg) (for 8 days) | 84810 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | female | 150.9 | g | acetaminophen (1000 mg/kg) (for 15 days) | 84811 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | female | 157.9 | g | acetaminophen (1000 mg/kg) (for 22 days) | 84812 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | female | 166.7 | g | acetaminophen (1000 mg/kg) (for 28 days) | 84813 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | body weight | SD | female | 137.3 | g | naive control condition | 84814 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 143.7 | g | naive control condition | 84815 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 151.6 | g | naive control condition | 84816 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 159.1 | g | naive control condition | 84817 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 160.5 | g | naive control condition | 84818 | naive control condition | | | | | | | | |

6 | body weight | SD | female | 139 | g | acetaminophen (1000 mg/kg) (for 1 days) | 84819 | acetaminophen (1000 mg/kg) (for 1 days) | | | | | | | | |

6 | body weight | SD | female | 146.1 | g | acetaminophen (1000 mg/kg) (for 8 days) | 84820 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | body weight | SD | female | 153.9 | g | acetaminophen (1000 mg/kg) (for 15 days) | 84821 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | body weight | SD | female | 160.7 | g | acetaminophen (1000 mg/kg) (for 22 days) | 84822 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | body weight | SD | female | 164.5 | g | acetaminophen (1000 mg/kg) (for 28 days) | 84823 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | male | 33.1 | g/d | naive control condition | 84824 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 35 | g/d | naive control condition | 84825 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 35.8 | g/d | naive control condition | 84826 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 31.9 | g/d | naive control condition | 84827 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 32.5 | g/d | acetaminophen (250 mg/kg) (for 8 days) | 84828 | acetaminophen (250 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | male | 34.3 | g/d | acetaminophen (250 mg/kg) (for 15 days) | 84829 | acetaminophen (250 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | male | 34.2 | g/d | acetaminophen (250 mg/kg) (for 22 days) | 84830 | acetaminophen (250 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | male | 32.4 | g/d | acetaminophen (250 mg/kg) (for 28 days) | 84831 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | male | 33.3 | g/d | acetaminophen (500 mg/kg) (for 8 days) | 84832 | acetaminophen (500 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | male | 36.7 | g/d | acetaminophen (500 mg/kg) (for 15 days) | 84833 | acetaminophen (500 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | male | 39.4 | g/d | acetaminophen (500 mg/kg) (for 22 days) | 84834 | acetaminophen (500 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | male | 31.7 | g/d | acetaminophen (500 mg/kg) (for 28 days) | 84835 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | male | 34.9 | g/d | acetaminophen (1000 mg/kg) (for 8 days) | 84836 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | male | 35.1 | g/d | acetaminophen (1000 mg/kg) (for 15 days) | 84837 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | male | 34.8 | g/d | acetaminophen (1000 mg/kg) (for 22 days) | 84838 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | male | 31 | g/d | acetaminophen (1000 mg/kg) (for 28 days) | 84839 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | male | 33.5 | g/d | naive control condition | 84840 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 34.5 | g/d | naive control condition | 84841 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 33.7 | g/d | naive control condition | 84842 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 27.9 | g/d | naive control condition | 84843 | naive control condition | | | | | | | | |

6 | food intake rate | SD | male | 39.5 | g/d | acetaminophen (1000 mg/kg) (for 8 days) | 84844 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | male | 34.9 | g/d | acetaminophen (1000 mg/kg) (for 15 days) | 84845 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | male | 39.4 | g/d | acetaminophen (1000 mg/kg) (for 22 days) | 84846 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | male | 33.6 | g/d | acetaminophen (1000 mg/kg) (for 28 days) | 84847 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | female | 22.4 | g/d | naive control condition | 84848 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 21.9 | g/d | naive control condition | 84849 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 24.5 | g/d | naive control condition | 84850 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 23.1 | g/d | naive control condition | 84851 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 21.3 | g/d | acetaminophen (250 mg/kg) (for 8 days) | 84852 | acetaminophen (250 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | female | 23 | g/d | acetaminophen (250 mg/kg) (for 15 days) | 84853 | acetaminophen (250 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | female | 23.5 | g/d | acetaminophen (250 mg/kg) (for 22 days) | 84854 | acetaminophen (250 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | female | 26 | g/d | acetaminophen (250 mg/kg) (for 28 days) | 84855 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | female | 19.9 | g/d | acetaminophen (500 mg/kg) (for 8 days) | 84856 | acetaminophen (500 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | female | 21.6 | g/d | acetaminophen (500 mg/kg) (for 15 days) | 84857 | acetaminophen (500 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | female | 21.6 | g/d | acetaminophen (500 mg/kg) (for 22 days) | 84858 | acetaminophen (500 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | female | 24.6 | g/d | acetaminophen (500 mg/kg) (for 28 days) | 84859 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | female | 21.8 | g/d | acetaminophen (1000 mg/kg) (for 8 days) | 84860 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | female | 25.2 | g/d | acetaminophen (1000 mg/kg) (for 15 days) | 84861 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | female | 26.6 | g/d | acetaminophen (1000 mg/kg) (for 22 days) | 84862 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | female | 25.7 | g/d | acetaminophen (1000 mg/kg) (for 28 days) | 84863 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | food intake rate | SD | female | 18.4 | g/d | naive control condition | 84864 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 21.4 | g/d | naive control condition | 84865 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 24.9 | g/d | naive control condition | 84866 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 20.4 | g/d | naive control condition | 84867 | naive control condition | | | | | | | | |

6 | food intake rate | SD | female | 18.5 | g/d | acetaminophen (1000 mg/kg) (for 8 days) | 84868 | acetaminophen (1000 mg/kg) (for 8 days) | | | | | | | | |

6 | food intake rate | SD | female | 20 | g/d | acetaminophen (1000 mg/kg) (for 15 days) | 84869 | acetaminophen (1000 mg/kg) (for 15 days) | | | | | | | | |

6 | food intake rate | SD | female | 24.6 | g/d | acetaminophen (1000 mg/kg) (for 22 days) | 84870 | acetaminophen (1000 mg/kg) (for 22 days) | | | | | | | | |

6 | food intake rate | SD | female | 21.8 | g/d | acetaminophen (1000 mg/kg) (for 28 days) | 84871 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | male | 6.56 | x 1000 cells/ul | naive control condition | 84885 | naive control condition | | | | | | | | |

6 | blood differential white blood cell count | SD | male | 11.3 | x 1000 cells/ul | acetaminophen (250 mg/kg) (for 28 days) | 84887 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | male | 7.68 | x 1000 cells/ul | acetaminophen (500 mg/kg) (for 28 days) | 84888 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | male | 7.58 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84890 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | male | 8.19 | x 1000 cells/ul | naive control condition | 84891 | naive control condition | | | | | | | | |

6 | blood differential white blood cell count | SD | male | 8.34 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84893 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | male | 8.31 | x 10E6 cells/ul | naive control condition | 84894 | naive control condition | | | | | | | | |

6 | red blood cell count | SD | male | 8.56 | x 10E6 cells/ul | acetaminophen (250 mg/kg) (for 28 days) | 84895 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | male | 8.47 | x 10E6 cells/ul | acetaminophen (500 mg/kg) (for 28 days) | 84896 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | male | 8.64 | x 10E6 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84897 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | male | 8.8 | x 10E6 cells/ul | naive control condition | 84898 | naive control condition | | | | | | | | |

6 | red blood cell count | SD | male | 8.64 | x 10E6 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84899 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | female | 6.1 | x 1000 cells/ul | naive control condition | 84901 | naive control condition | | | | | | | | |

6 | blood differential white blood cell count | SD | female | 8.83 | x 1000 cells/ul | acetaminophen (250 mg/kg) (for 28 days) | 84902 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | female | 8.81 | x 1000 cells/ul | acetaminophen (500 mg/kg) (for 28 days) | 84904 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | female | 9.48 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84905 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood differential white blood cell count | SD | female | 8.24 | x 1000 cells/ul | naive control condition | 84906 | naive control condition | | | | | | | | |

6 | blood differential white blood cell count | SD | female | 8.68 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84907 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | female | 8.26 | x 10E6 cells/ul | naive control condition | 84908 | naive control condition | | | | | | | | |

6 | red blood cell count | SD | female | 8.61 | x 10E6 cells/ul | acetaminophen (250 mg/kg) (for 28 days) | 84909 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | female | 8.93 | x 10E6 cells/ul | acetaminophen (500 mg/kg) (for 28 days) | 84911 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | female | 8.97 | x 10E6 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84912 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell count | SD | female | 8.77 | x 10E6 cells/ul | naive control condition | 84913 | naive control condition | | | | | | | | |

6 | red blood cell count | SD | female | 8.97 | x 10E6 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84914 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | male | 13.8 | g/dl | naive control condition | 84939 | naive control condition | | | | | | | | |

6 | blood hemoglobin level | SD | male | 14.02 | g/dl | acetaminophen (250 mg/kg) (for 28 days) | 84940 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | male | 13.68 | g/dl | acetaminophen (500 mg/kg) (for 28 days) | 84941 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | male | 13.98 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84942 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | male | 13.9 | g/dl | naive control condition | 84943 | naive control condition | | | | | | | | |

6 | blood hemoglobin level | SD | male | 13.75 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84944 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | female | 11.28 | g/dl | naive control condition | 84945 | naive control condition | | | | | | | | |

6 | blood hemoglobin level | SD | female | 11.57 | g/dl | acetaminophen (250 mg/kg) (for 28 days) | 84946 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | female | 11.9 | g/dl | acetaminophen (500 mg/kg) (for 28 days) | 84947 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | female | 12.98 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84948 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood hemoglobin level | SD | female | 11.02 | g/dl | naive control condition | 84949 | naive control condition | | | | | | | | |

6 | blood hemoglobin level | SD | female | 12.38 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84950 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | male | 45.25 | % | naive control condition | 84951 | naive control condition | | | | | | | | |

6 | hematocrit | SD | male | 44.38 | % | acetaminophen (250 mg/kg) (for 28 days) | 84952 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | male | 44.05 | % | acetaminophen (500 mg/kg) (for 28 days) | 84953 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | male | 45.1 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84954 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | male | 45.68 | % | naive control condition | 84955 | naive control condition | | | | | | | | |

6 | hematocrit | SD | male | 45.18 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84956 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | female | 41.03 | % | naive control condition | 84957 | naive control condition | | | | | | | | |

6 | hematocrit | SD | female | 40.22 | % | acetaminophen (250 mg/kg) (for 28 days) | 84958 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | female | 40.85 | % | acetaminophen (500 mg/kg) (for 28 days) | 84959 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | female | 41.85 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84960 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | hematocrit | SD | female | 39.8 | % | naive control condition | 84961 | naive control condition | | | | | | | | |

6 | hematocrit | SD | female | 41.5 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84962 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 11.57 | % | naive control condition | 84963 | naive control condition | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 12.35 | % | acetaminophen (250 mg/kg) (for 28 days) | 84964 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 11.97 | % | acetaminophen (500 mg/kg) (for 28 days) | 84965 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 11.87 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84966 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 11.9 | % | naive control condition | 84967 | naive control condition | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 11.73 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84968 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | female | 10.98 | % | naive control condition | 84969 | naive control condition | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | female | 11.38 | % | acetaminophen (250 mg/kg) (for 28 days) | 84970 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | female | 12.62 | % | acetaminophen (500 mg/kg) (for 28 days) | 84971 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | female | 11.13 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84972 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | female | 11.32 | % | naive control condition | 84973 | naive control condition | | | | | | | | |

6 | red blood cell distribution width-coefficient of variation | SD | male | 11.35 | % | acetaminophen (1000 mg/kg) (for 28 days) | 84974 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | male | 1095.83 | x 1000 cells/ul | naive control condition | 84975 | naive control condition | | | | | | | | |

6 | platelet count | SD | male | 1148.83 | x 1000 cells/ul | acetaminophen (250 mg/kg) (for 28 days) | 84976 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | male | 1177.5 | x 1000 cells/ul | acetaminophen (500 mg/kg) (for 28 days) | 84977 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | male | 1263 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84978 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | male | 1171 | x 1000 cells/ul | naive control condition | 84979 | naive control condition | | | | | | | | |

6 | platelet count | SD | male | 1122.17 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84980 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | female | 816 | x 1000 cells/ul | naive control condition | 84981 | naive control condition | | | | | | | | |

6 | platelet count | SD | female | 855.83 | x 1000 cells/ul | acetaminophen (250 mg/kg) (for 28 days) | 84982 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | female | 919 | x 1000 cells/ul | acetaminophen (500 mg/kg) (for 28 days) | 84983 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | female | 1025.83 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84984 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | platelet count | SD | female | 846 | x 1000 cells/ul | naive control condition | 84985 | naive control condition | | | | | | | | |

6 | platelet count | SD | female | 931 | x 1000 cells/ul | acetaminophen (1000 mg/kg) (for 28 days) | 84986 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | male | 115.3 | mg/dl | naive control condition | 84987 | naive control condition | | | | | | | | |

6 | blood glucose level | SD | male | 103.7 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 84988 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | male | 127 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 84989 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | male | 86.8 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84990 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | male | 72.48 | mg/dl | naive control condition | 84991 | naive control condition | | | | | | | | |

6 | blood glucose level | SD | male | 62.11 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84992 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | female | 70.7 | mg/dl | naive control condition | 84993 | naive control condition | | | | | | | | |

6 | blood glucose level | SD | female | 109.2 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 84994 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | female | 116.2 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 84995 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | female | 181.5 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84996 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood glucose level | SD | female | 82.67 | mg/dl | naive control condition | 84997 | naive control condition | | | | | | | | |

6 | blood glucose level | SD | female | 90.83 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 84998 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | male | 3.3 | g/dl | naive control condition | 84999 | naive control condition | | | | | | | | |

6 | blood albumin level | SD | male | 3.3 | g/dl | acetaminophen (250 mg/kg) (for 28 days) | 85000 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | male | 3.2 | g/dl | acetaminophen (500 mg/kg) (for 28 days) | 85001 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | male | 3.5 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85002 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | male | 2.93 | g/dl | naive control condition | 85003 | naive control condition | | | | | | | | |

6 | blood albumin level | SD | male | 2.48 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85004 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | female | 3.5 | g/dl | naive control condition | 85005 | naive control condition | | | | | | | | |

6 | blood albumin level | SD | female | 3.5 | g/dl | acetaminophen (250 mg/kg) (for 28 days) | 85006 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | female | 3.3 | g/dl | acetaminophen (500 mg/kg) (for 28 days) | 85007 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | female | 4.6 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85008 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level | SD | female | 3.6 | g/dl | naive control condition | 85009 | naive control condition | | | | | | | | |

6 | blood albumin level | SD | female | 3.62 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85010 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | male | 63 | mg/ml | naive control condition | 85011 | naive control condition | | | | | | | | |

6 | plasma total protein level | SD | male | 63 | mg/ml | acetaminophen (250 mg/kg) (for 28 days) | 85012 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | male | 62 | mg/ml | acetaminophen (500 mg/kg) (for 28 days) | 85013 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | male | 65 | mg/ml | acetaminophen (1000 mg/kg) (for 28 days) | 85014 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | male | 54.3 | mg/ml | naive control condition | 85015 | naive control condition | | | | | | | | |

6 | plasma total protein level | SD | male | 46 | mg/ml | acetaminophen (1000 mg/kg) (for 28 days) | 85016 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | female | 65 | mg/ml | naive control condition | 85017 | naive control condition | | | | | | | | |

6 | plasma total protein level | SD | female | 64 | mg/ml | acetaminophen (250 mg/kg) (for 28 days) | 85018 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | female | 62 | mg/ml | acetaminophen (500 mg/kg) (for 28 days) | 85019 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | female | 83 | mg/ml | acetaminophen (1000 mg/kg) (for 28 days) | 85020 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | plasma total protein level | SD | female | 66 | mg/ml | naive control condition | 85021 | naive control condition | | | | | | | | |

6 | plasma total protein level | SD | female | 67 | mg/ml | acetaminophen (1000 mg/kg) (for 28 days) | 85022 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | male | 2.9 | g/dl | naive control condition | 85023 | naive control condition | | | | | | | | |

6 | blood globulin level | SD | male | 3 | g/dl | acetaminophen (250 mg/kg) (for 28 days) | 85024 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | male | 2.9 | g/dl | acetaminophen (500 mg/kg) (for 28 days) | 85025 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | male | 3 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85026 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | male | 2.5 | g/dl | naive control condition | 85027 | naive control condition | | | | | | | | |

6 | blood globulin level | SD | male | 2.12 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85028 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | female | 3 | g/dl | naive control condition | 85029 | naive control condition | | | | | | | | |

6 | blood globulin level | SD | female | 3 | g/dl | acetaminophen (250 mg/kg) (for 28 days) | 85030 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | female | 2.9 | g/dl | acetaminophen (500 mg/kg) (for 28 days) | 85031 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | female | 3.8 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85032 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood globulin level | SD | female | 3 | g/dl | naive control condition | 85033 | naive control condition | | | | | | | | |

6 | blood globulin level | SD | female | 3.08 | g/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85034 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | male | 16 | mg/dl | naive control condition | 85035 | naive control condition | | | | | | | | |

6 | blood urea nitrogen level | SD | male | 14.5 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85036 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | male | 14.2 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85037 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | male | 15.5 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85038 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | male | 13.56 | mg/dl | naive control condition | 85039 | naive control condition | | | | | | | | |

6 | blood urea nitrogen level | SD | male | 10.97 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85040 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | female | 18.7 | mg/dl | naive control condition | 85041 | naive control condition | | | | | | | | |

6 | blood urea nitrogen level | SD | female | 13.3 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85042 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | female | 15.5 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85043 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | female | 38.2 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85044 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood urea nitrogen level | SD | female | 16 | mg/dl | naive control condition | 85045 | naive control condition | | | | | | | | |

6 | blood urea nitrogen level | SD | female | 21 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85046 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | male | 0.8 | | naive control condition | 85047 | naive control condition | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | male | 0.9 | | acetaminophen (250 mg/kg) (for 28 days) | 85048 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | male | 0.9 | | acetaminophen (500 mg/kg) (for 28 days) | 85049 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | male | 0.9 | | acetaminophen (1000 mg/kg) (for 28 days) | 85050 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | male | 0.77 | | naive control condition | 85051 | naive control condition | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | male | 0.66 | | acetaminophen (1000 mg/kg) (for 28 days) | 85052 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | female | 0.9 | | naive control condition | 85053 | naive control condition | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | female | 1.1 | | acetaminophen (250 mg/kg) (for 28 days) | 85054 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | female | 1.1 | | acetaminophen (500 mg/kg) (for 28 days) | 85055 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | female | 1 | | acetaminophen (1000 mg/kg) (for 28 days) | 85056 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | female | 0.93 | | naive control condition | 85057 | naive control condition | | | | | | | | |

6 | blood albumin level to blood globulin level ratio | SD | female | 0.97 | | acetaminophen (1000 mg/kg) (for 28 days) | 85058 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | male | 0.5 | mg/dl | naive control condition | 85059 | naive control condition | | | | | | | | |

6 | blood creatinine level | SD | male | 0.4 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85060 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | male | 0.4 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85061 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | male | 0.4 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85062 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | male | 0.37 | mg/dl | naive control condition | 85063 | naive control condition | | | | | | | | |

6 | blood creatinine level | SD | male | 0.3 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85064 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | female | 0.4 | mg/dl | naive control condition | 85065 | naive control condition | | | | | | | | |

6 | blood creatinine level | SD | female | 0.4 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85066 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | female | 0.3 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85067 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | female | 1.1 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85068 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood creatinine level | SD | female | 0.33 | mg/dl | naive control condition | 85069 | naive control condition | | | | | | | | |

6 | blood creatinine level | SD | female | 0.33 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85070 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | male | 169.7 | U/l | naive control condition | 85071 | naive control condition | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | male | 136.8 | U/l | acetaminophen (250 mg/kg) (for 28 days) | 85072 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | male | 140.8 | U/l | acetaminophen (500 mg/kg) (for 28 days) | 85073 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | male | 178.5 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85074 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | male | 145.57 | U/l | naive control condition | 85075 | naive control condition | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | male | 125.07 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85076 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | female | 162.23 | U/l | naive control condition | 85077 | naive control condition | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | female | 118.67 | U/l | acetaminophen (250 mg/kg) (for 28 days) | 85078 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | female | 116.83 | U/l | acetaminophen (500 mg/kg) (for 28 days) | 85079 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | female | 263.17 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85080 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | female | 155.67 | U/l | naive control condition | 85081 | naive control condition | | | | | | | | |

6 | blood aspartate aminotransferase activity level | SD | female | 146.5 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85082 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | male | 46.7 | U/l | naive control condition | 85083 | naive control condition | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | male | 59.2 | U/l | acetaminophen (250 mg/kg) (for 28 days) | 85084 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | male | 59.8 | U/l | acetaminophen (500 mg/kg) (for 28 days) | 85085 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | male | 54 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85086 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | male | 46.73 | U/l | naive control condition | 85087 | naive control condition | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | male | 39.74 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85088 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | female | 46.83 | U/l | naive control condition | 85089 | naive control condition | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | female | 57.33 | U/l | acetaminophen (250 mg/kg) (for 28 days) | 85090 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | female | 59.67 | U/l | acetaminophen (500 mg/kg) (for 28 days) | 85091 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | female | 42.5 | U/l | naive control condition | 85092 | naive control condition | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | female | 49.67 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85093 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alanine aminotransferase activity level | SD | female | 116.5 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85094 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | male | 298.5 | U/l | naive control condition | 85095 | naive control condition | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | male | 469 | U/l | acetaminophen (250 mg/kg) (for 28 days) | 85096 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | male | 327.2 | U/l | acetaminophen (500 mg/kg) (for 28 days) | 85097 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | male | 295.8 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85098 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | male | 268.14 | U/l | naive control condition | 85099 | naive control condition | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | male | 245.33 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85100 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | female | 206 | U/l | naive control condition | 85101 | naive control condition | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | female | 353.33 | U/l | acetaminophen (250 mg/kg) (for 28 days) | 85102 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | female | 416.5 | U/l | acetaminophen (500 mg/kg) (for 28 days) | 85103 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | female | 423.17 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85104 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | female | 178.67 | U/l | naive control condition | 85105 | naive control condition | | | | | | | | |

6 | blood alkaline phosphatase activity level | SD | female | 228.17 | U/l | acetaminophen (1000 mg/kg) (for 28 days) | 85106 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | male | 0.3 | mg/dl | naive control condition | 85107 | naive control condition | | | | | | | | |

6 | blood bilirubin level | SD | male | 0.41 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85108 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | male | 0.41 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85109 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | male | 0.47 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85110 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | male | 0.52 | mg/dl | naive control condition | 85111 | naive control condition | | | | | | | | |

6 | blood bilirubin level | SD | male | 0.55 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85112 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | female | 0.44 | mg/dl | naive control condition | 85113 | naive control condition | | | | | | | | |

6 | blood bilirubin level | SD | female | 0.34 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85114 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | female | 0.39 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85115 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | female | 1.33 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85116 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood bilirubin level | SD | female | 0.6 | mg/dl | naive control condition | 85117 | naive control condition | | | | | | | | |

6 | blood bilirubin level | SD | female | 0.63 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85118 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | male | 143.8 | mmol/l | naive control condition | 85119 | naive control condition | | | | | | | | |

6 | blood sodium level | SD | male | 144.7 | mmol/l | acetaminophen (250 mg/kg) (for 28 days) | 85120 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | male | 145.2 | mmol/l | acetaminophen (500 mg/kg) (for 28 days) | 85121 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | male | 147.8 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85122 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | male | 123.26 | mmol/l | naive control condition | 85123 | naive control condition | | | | | | | | |

6 | blood sodium level | SD | male | 104.23 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85124 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | female | 146.5 | mmol/l | naive control condition | 85125 | naive control condition | | | | | | | | |

6 | blood sodium level | SD | female | 146.67 | mmol/l | acetaminophen (250 mg/kg) (for 28 days) | 85126 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | female | 146.67 | mmol/l | acetaminophen (500 mg/kg) (for 28 days) | 85127 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | female | 150.33 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85128 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood sodium level | SD | female | 144.33 | mmol/l | naive control condition | 85129 | naive control condition | | | | | | | | |

6 | blood sodium level | SD | female | 145.33 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85130 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | male | 5 | mmol/l | naive control condition | 85131 | naive control condition | | | | | | | | |

6 | blood potassium level | SD | male | 5 | mmol/l | acetaminophen (250 mg/kg) (for 28 days) | 85132 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | male | 5 | mmol/l | acetaminophen (500 mg/kg) (for 28 days) | 85133 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | male | 5.4 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85134 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | male | 4.6 | mmol/l | naive control condition | 85135 | naive control condition | | | | | | | | |

6 | blood potassium level | SD | male | 3.88 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85136 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | female | 4.57 | mmol/l | naive control condition | 85137 | naive control condition | | | | | | | | |

6 | blood potassium level | SD | female | 4.6 | mmol/l | acetaminophen (250 mg/kg) (for 28 days) | 85138 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | female | 4.75 | mmol/l | acetaminophen (500 mg/kg) (for 28 days) | 85139 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | female | 2.27 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85140 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood potassium level | SD | female | 4.7 | mmol/l | naive control condition | 85141 | naive control condition | | | | | | | | |

6 | blood potassium level | SD | female | 4.77 | mmol/l | acetaminophen (1000 mg/kg) (for 28 days) | 85142 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | male | 10 | mg/dl | naive control condition | 85143 | naive control condition | | | | | | | | |

6 | blood calcium level | SD | male | 10 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85144 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | male | 10.2 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85145 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | male | 9.9 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85146 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | male | 8.27 | mg/dl | naive control condition | 85147 | naive control condition | | | | | | | | |

6 | blood calcium level | SD | male | 7.03 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85148 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | female | 9.95 | mg/dl | naive control condition | 85149 | naive control condition | | | | | | | | |

6 | blood calcium level | SD | female | 10.05 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85150 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | female | 10 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85151 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | female | 10.42 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85152 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood calcium level | SD | female | 10.23 | mg/dl | naive control condition | 85153 | naive control condition | | | | | | | | |

6 | blood calcium level | SD | female | 10.08 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85154 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | male | 6.3 | mg/dl | naive control condition | 85155 | naive control condition | | | | | | | | |

6 | blood phosphate level | SD | male | 6 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85156 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | male | 6.1 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85157 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | male | 5.9 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85158 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | male | 4.87 | mg/dl | naive control condition | 85159 | naive control condition | | | | | | | | |

6 | blood phosphate level | SD | male | 4.06 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85160 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | female | 5.6 | mg/dl | naive control condition | 85161 | naive control condition | | | | | | | | |

6 | blood phosphate level | SD | female | 5.88 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85162 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | female | 5.98 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85163 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | female | 6.53 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85164 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood phosphate level | SD | female | 5.45 | mg/dl | naive control condition | 85165 | naive control condition | | | | | | | | |

6 | blood phosphate level | SD | female | 5.5 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85166 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | male | 78 | mg/dl | naive control condition | 85167 | naive control condition | | | | | | | | |

6 | blood total cholesterol level | SD | male | 92.8 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85168 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | male | 87.8 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85169 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | male | 86.8 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85170 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | male | 73.99 | mg/dl | naive control condition | 85171 | naive control condition | | | | | | | | |

6 | blood total cholesterol level | SD | male | 60.1 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85172 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | female | 102.5 | mg/dl | naive control condition | 85173 | naive control condition | | | | | | | | |

6 | blood total cholesterol level | SD | female | 92.2 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85174 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | female | 102.3 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85175 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | female | 96.5 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85176 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood total cholesterol level | SD | female | 112.17 | mg/dl | naive control condition | 85177 | naive control condition | | | | | | | | |

6 | blood total cholesterol level | SD | female | 109.17 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85178 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | male | 52.3 | mg/dl | naive control condition | 85179 | naive control condition | | | | | | | | |

6 | blood triglyceride level | SD | male | 141.2 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85180 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | male | 109.5 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85181 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | male | 92.3 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85182 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | male | 65.45 | mg/dl | naive control condition | 85183 | naive control condition | | | | | | | | |

6 | blood triglyceride level | SD | male | 58.81 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85184 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | female | 22.8 | mg/dl | naive control condition | 85185 | naive control condition | | | | | | | | |

6 | blood triglyceride level | SD | female | 27.7 | mg/dl | acetaminophen (250 mg/kg) (for 28 days) | 85186 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | female | 44 | mg/dl | acetaminophen (500 mg/kg) (for 28 days) | 85187 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | female | 31.7 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85188 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | blood triglyceride level | SD | female | 32.67 | mg/dl | naive control condition | 85189 | naive control condition | | | | | | | | |

6 | blood triglyceride level | SD | female | 23.83 | mg/dl | acetaminophen (1000 mg/kg) (for 28 days) | 85190 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | male | 3.81 | g | naive control condition | 85191 | naive control condition | | | | | | | | |

6 | liver wet weight | SD | male | 4.31 | g | acetaminophen (250 mg/kg) (for 28 days) | 85192 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | male | 4.31 | g | acetaminophen (500 mg/kg) (for 28 days) | 85193 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | male | 3.65 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85194 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | male | 3.18 | g | naive control condition | 85195 | naive control condition | | | | | | | | |

6 | liver wet weight | SD | male | 3.56 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85196 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | female | 3.64 | g | naive control condition | 85200 | naive control condition | | | | | | | | |

6 | liver wet weight | SD | female | 4.06 | g | acetaminophen (250 mg/kg) (for 28 days) | 85201 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | female | 4.2 | g | acetaminophen (500 mg/kg) (for 28 days) | 85202 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | female | 3.7 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85203 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | liver wet weight | SD | female | 3.69 | g | naive control condition | 85204 | naive control condition | | | | | | | | |

6 | liver wet weight | SD | female | 3.51 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85205 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | male | 0.89 | g | naive control condition | 85206 | naive control condition | | | | | | | | |

6 | both kidneys wet weight | SD | male | 0.88 | g | acetaminophen (250 mg/kg) (for 28 days) | 85207 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | male | 0.85 | g | acetaminophen (500 mg/kg) (for 28 days) | 85208 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | male | 0.88 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85209 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | male | 0.76 | g | naive control condition | 85210 | naive control condition | | | | | | | | |

6 | both kidneys wet weight | SD | male | 0.84 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85211 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | female | 0.94 | g | naive control condition | 85212 | naive control condition | | | | | | | | |

6 | both kidneys wet weight | SD | female | 0.85 | g | acetaminophen (250 mg/kg) (for 28 days) | 85213 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | female | 0.88 | g | acetaminophen (500 mg/kg) (for 28 days) | 85214 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | female | 0.92 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85215 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both kidneys wet weight | SD | female | 0.87 | g | naive control condition | 85216 | naive control condition | | | | | | | | |

6 | both kidneys wet weight | SD | female | 0.88 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85217 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | male | 0.73 | g | naive control condition | 85218 | naive control condition | | | | | | | | |

6 | both lungs wet weight | SD | male | 0.72 | g | acetaminophen (250 mg/kg) (for 28 days) | 85219 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | male | 0.68 | g | acetaminophen (500 mg/kg) (for 28 days) | 85220 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | male | 0.77 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85221 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | male | 0.66 | g | naive control condition | 85222 | naive control condition | | | | | | | | |

6 | both lungs wet weight | SD | male | 0.64 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85223 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | female | 0.81 | g | naive control condition | 85224 | naive control condition | | | | | | | | |

6 | both lungs wet weight | SD | female | 0.76 | g | acetaminophen (250 mg/kg) (for 28 days) | 85225 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | female | 0.8 | g | acetaminophen (500 mg/kg) (for 28 days) | 85226 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | female | 0.73 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85227 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | both lungs wet weight | SD | female | 0.79 | g | naive control condition | 85228 | naive control condition | | | | | | | | |

6 | both lungs wet weight | SD | female | 0.74 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85229 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | male | 0.39 | g | naive control condition | 85230 | naive control condition | | | | | | | | |

6 | heart wet weight | SD | male | 0.37 | g | acetaminophen (250 mg/kg) (for 28 days) | 85231 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | male | 0.37 | g | acetaminophen (500 mg/kg) (for 28 days) | 85232 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | male | 0.37 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85233 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | male | 0.33 | g | naive control condition | 85234 | naive control condition | | | | | | | | |

6 | heart wet weight | SD | male | 0.36 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85235 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | female | 0.4 | g | naive control condition | 85236 | naive control condition | | | | | | | | |

6 | heart wet weight | SD | female | 0.41 | g | acetaminophen (250 mg/kg) (for 28 days) | 85237 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | female | 0.42 | g | acetaminophen (500 mg/kg) (for 28 days) | 85238 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | female | 0.42 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85239 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | heart wet weight | SD | female | 0.44 | g | naive control condition | 85240 | naive control condition | | | | | | | | |

6 | heart wet weight | SD | male | 0.41 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85241 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | male | 0.22 | g | naive control condition | 85242 | naive control condition | | | | | | | | |

6 | spleen wet weight | SD | male | 0.29 | g | acetaminophen (250 mg/kg) (for 28 days) | 85243 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | male | 0.2 | g | acetaminophen (500 mg/kg) (for 28 days) | 85244 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | male | 0.21 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85245 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | male | 0.17 | g | naive control condition | 85246 | naive control condition | | | | | | | | |

6 | spleen wet weight | SD | male | 0.21 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85247 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | female | 0.24 | g | naive control condition | 85248 | naive control condition | | | | | | | | |

6 | spleen wet weight | SD | female | 0.24 | g | acetaminophen (250 mg/kg) (for 28 days) | 85249 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | female | 0.26 | g | acetaminophen (500 mg/kg) (for 28 days) | 85250 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | female | 0.24 | g | naive control condition | 85251 | naive control condition | | | | | | | | |

6 | spleen wet weight | SD | female | 0.24 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85252 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | spleen wet weight | SD | female | 0.23 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85253 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | male | 0.77 | g | naive control condition | 85254 | naive control condition | | | | | | | | |

6 | brain wet weight | SD | male | 0.72 | g | acetaminophen (250 mg/kg) (for 28 days) | 85255 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | male | 0.74 | g | acetaminophen (500 mg/kg) (for 28 days) | 85256 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | male | 0.75 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85257 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | male | 0.67 | g | naive control condition | 85258 | naive control condition | | | | | | | | |

6 | brain wet weight | SD | male | 0.68 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85259 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | female | 1.1 | g | naive control condition | 85260 | naive control condition | | | | | | | | |

6 | brain wet weight | SD | female | 1.03 | g | acetaminophen (250 mg/kg) (for 28 days) | 85261 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | female | 1.11 | g | acetaminophen (500 mg/kg) (for 28 days) | 85262 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | female | 1.17 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85263 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | brain wet weight | SD | female | 1.09 | g | naive control condition | 85264 | naive control condition | | | | | | | | |

6 | brain wet weight | SD | female | 1.09 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85265 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | male | 0.02 | g | naive control condition | 85266 | naive control condition | | | | | | | | |

6 | adrenal gland wet weight | SD | male | 0.02 | g | acetaminophen (250 mg/kg) (for 28 days) | 85267 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | male | 0.02 | g | acetaminophen (500 mg/kg) (for 28 days) | 85268 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | male | 0.02 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85269 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | male | 0.02 | g | naive control condition | 85270 | naive control condition | | | | | | | | |

6 | adrenal gland wet weight | SD | male | 0.02 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85271 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | female | 0.04 | g | naive control condition | 85272 | naive control condition | | | | | | | | |

6 | adrenal gland wet weight | SD | female | 0.04 | g | acetaminophen (250 mg/kg) (for 28 days) | 85273 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | female | 0.04 | g | acetaminophen (500 mg/kg) (for 28 days) | 85274 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | female | 0.04 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85275 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | adrenal gland wet weight | SD | female | 0.04 | g | naive control condition | 85276 | naive control condition | | | | | | | | |

6 | adrenal gland wet weight | SD | female | 0.04 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85277 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | testis wet weight | SD | male | 1.17 | g | naive control condition | 85278 | naive control condition | | | | | | | | |

6 | testis wet weight | SD | male | 1.19 | g | acetaminophen (250 mg/kg) (for 28 days) | 85279 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | testis wet weight | SD | male | 1.17 | g | acetaminophen (500 mg/kg) (for 28 days) | 85280 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | testis wet weight | SD | male | 1.03 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85281 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | testis wet weight | SD | male | 1 | g | naive control condition | 85282 | naive control condition | | | | | | | | |

6 | testis wet weight | SD | male | 1.01 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85283 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | uterus wet weight | SD | female | 0.35 | g | naive control condition | 85284 | naive control condition | | | | | | | | |

6 | uterus wet weight | SD | female | 0.28 | g | acetaminophen (250 mg/kg) (for 28 days) | 85285 | acetaminophen (250 mg/kg) (for 28 days) | | | | | | | | |

6 | uterus wet weight | SD | female | 0.45 | g | acetaminophen (500 mg/kg) (for 28 days) | 85286 | acetaminophen (500 mg/kg) (for 28 days) | | | | | | | | |

6 | uterus wet weight | SD | female | 0.38 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85287 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

6 | uterus wet weight | SD | female | 0.35 | g | naive control condition | 85288 | naive control condition | | | | | | | | |

6 | uterus wet weight | SD | female | 0.27 | g | acetaminophen (1000 mg/kg) (for 28 days) | 85289 | acetaminophen (1000 mg/kg) (for 28 days) | | | | | | | | |

16 | duration of loss of righting reflex | SD | female | 178 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98198 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

14 | duration of loss of righting reflex | SD | female | 129 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98199 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

38 | duration of loss of righting reflex | SD | female | 181 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98200 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

34 | duration of loss of righting reflex | SD | female | 228 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98201 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

25 | duration of loss of righting reflex | SD | female | 223 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98202 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

19 | duration of loss of righting reflex | SD | female | 222 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98203 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 724 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98204 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

14 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 954 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98211 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

21 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1241 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98212 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

23 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1131 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98213 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

16 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1263 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98214 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

10 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1334 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98215 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | number of entries into a discrete space in an experimental apparatus | SD | female | 15.6 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98216 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

14 | number of entries into a discrete space in an experimental apparatus | SD | female | 22.8 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98217 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

21 | number of entries into a discrete space in an experimental apparatus | SD | female | 29.7 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98218 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

23 | number of entries into a discrete space in an experimental apparatus | SD | female | 26.8 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98219 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

16 | number of entries into a discrete space in an experimental apparatus | SD | female | 34 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98220 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

10 | number of entries into a discrete space in an experimental apparatus | SD | female | 35.3 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98221 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 42.2 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98222 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

14 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 58.7 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98223 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

21 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 75.6 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98224 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

23 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 50.7 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98225 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

16 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 78.4 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98226 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

10 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 98.1 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98227 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | time to locate a hidden target platform in an experimental apparatus | SD | female | 48.8 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98228 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

8 | time to locate a hidden target platform in an experimental apparatus | SD | female | 17.8 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98229 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

8 | time to locate a hidden target platform in an experimental apparatus | SD | female | 21.2 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98230 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

14 | time to locate a hidden target platform in an experimental apparatus | SD | female | 37.5 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98232 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

14 | time to locate a hidden target platform in an experimental apparatus | SD | female | 15.8 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98233 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

14 | time to locate a hidden target platform in an experimental apparatus | SD | female | 18 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | 98234 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (140 rad/s2) (for 0 hours) | |

21 | time to locate a hidden target platform in an experimental apparatus | SD | female | 34.5 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98235 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

21 | time to locate a hidden target platform in an experimental apparatus | SD | female | 23.1 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98236 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

21 | time to locate a hidden target platform in an experimental apparatus | SD | female | 21.2 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98237 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

23 | time to locate a hidden target platform in an experimental apparatus | SD | female | 37.8 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98238 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

23 | time to locate a hidden target platform in an experimental apparatus | SD | female | 21.3 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98239 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

23 | time to locate a hidden target platform in an experimental apparatus | SD | female | 18.9 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98240 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

16 | time to locate a hidden target platform in an experimental apparatus | SD | female | 38.2 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98241 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

16 | time to locate a hidden target platform in an experimental apparatus | SD | female | 21.5 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98242 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

16 | time to locate a hidden target platform in an experimental apparatus | SD | female | 14.9 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98243 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

10 | time to locate a hidden target platform in an experimental apparatus | SD | female | 36 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98244 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

10 | time to locate a hidden target platform in an experimental apparatus | SD | female | 15.8 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98245 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

10 | time to locate a hidden target platform in an experimental apparatus | SD | female | 15.2 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98246 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1317 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98247 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

17 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 915 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98248 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

11 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1168 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98249 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

9 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 1101 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98250 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

9 | total horizontal distance resulting from voluntary locomotion in an experimental apparatus | SD | female | 777 | cm | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98251 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | number of entries into a discrete space in an experimental apparatus | SD | female | 29.3 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98252 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

17 | number of entries into a discrete space in an experimental apparatus | SD | female | 23.1 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98253 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

11 | number of entries into a discrete space in an experimental apparatus | SD | female | 1168 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98254 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

9 | number of entries into a discrete space in an experimental apparatus | SD | female | 24.5 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98255 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

9 | number of entries into a discrete space in an experimental apparatus | SD | female | 18.4 | | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98256 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 65.1 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98257 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

17 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 64.9 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98258 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

11 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 90.8 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98259 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

9 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 79.3 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98260 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

9 | amount of experiment time spent in a discrete space in an experimental apparatus | SD | female | 51.9 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98261 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

8 | time to locate a hidden target platform in an experimental apparatus | SD | female | 24.1 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98262 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

8 | time to locate a hidden target platform in an experimental apparatus | SD | female | 18.9 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98263 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

8 | time to locate a hidden target platform in an experimental apparatus | SD | female | 10 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) | 98264 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | | | |

17 | time to locate a hidden target platform in an experimental apparatus | SD | female | 41.7 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98265 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

17 | time to locate a hidden target platform in an experimental apparatus | SD | female | 16.7 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98266 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

17 | time to locate a hidden target platform in an experimental apparatus | SD | female | 13.6 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98267 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (210 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

11 | time to locate a hidden target platform in an experimental apparatus | SD | female | 38.5 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98268 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

11 | time to locate a hidden target platform in an experimental apparatus | SD | female | 13 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98269 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

11 | time to locate a hidden target platform in an experimental apparatus | SD | female | 10.1 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | 98270 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (250 rad/s2) (for 0 hours) | |

9 | time to locate a hidden target platform in an experimental apparatus | SD | female | 28 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98271 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

9 | time to locate a hidden target platform in an experimental apparatus | SD | female | 20.6 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98272 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

9 | time to locate a hidden target platform in an experimental apparatus | SD | female | 17 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | 98273 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (360 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (380 rad/s2) (for 0 hours) | |

9 | time to locate a hidden target platform in an experimental apparatus | SD | female | 31 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98274 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

9 | time to locate a hidden target platform in an experimental apparatus | SD | female | 15.7 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98275 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

9 | time to locate a hidden target platform in an experimental apparatus | SD | female | 10.5 | s | isoflurane (4 %) (between 0.1 and 0.2 hours) then carprofen (5 mg/kg) (for 0 hours) then coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) and coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | 98276 | isoflurane (4 %) (between 0.1 and 0.2 hours) | | | carprofen (5 mg/kg) (for 0 hours) | | | coronal plane rotational acceleration of the head (500 krad/s2) (for 0 hours) | coronal plane rotational acceleration of the head (615 rad/s2) (for 0 hours) | |

6 | serum testosterone level | SD | male | 0.4 | ng/ml | in utero condition (for 7 days) and dibutyl phthalate (850 mg/kg/d) (for 7 days) | 98731 | in utero condition (for 7 days) | dibutyl phthalate (850 mg/kg/d) (for 7 days) | | | | | | | |

6 | serum testosterone level | SD | male | 0.81 | ng/ml | in utero condition (for 7 days) and corn oil (for 7 days) | 98732 | in utero condition (for 7 days) | corn oil (for 7 days) | | | | | | | |

43 | body weight | SD | male | 4.9 | g | in utero condition (for 7 days) and dibutyl phthalate (850 mg/kg/d) (for 7 days) | 98735 | in utero condition (for 7 days) | dibutyl phthalate (850 mg/kg/d) (for 7 days) | | | | | | | |

N/A | body weight | SD | male | 6.34 | g | in utero condition (for 7 days) and corn oil (for 7 days) | 98736 | in utero condition (for 7 days) | corn oil (for 7 days) | | | | | | | |

43 | anogenital distance to cube root of body weight ratio | SD | male | 1.48 | | in utero condition (for 7 days) and dibutyl phthalate (850 mg/kg/d) (for 7 days) | 98737 | in utero condition (for 7 days) | dibutyl phthalate (850 mg/kg/d) (for 7 days) | | | | | | | |

N/A | anogenital distance to cube root of body weight ratio | SD | male | 1.57 | | in utero condition (for 7 days) and corn oil (for 7 days) | 98738 | in utero condition (for 7 days) | corn oil (for 7 days) | | | | | | | |

6 | body weight | SD | male | 302 | g | artificial aortocaval fistula (for 6 hours) | 98755 | artificial aortocaval fistula (for 6 hours) | | | | | | | | |

6 | body weight | SD | male | 291 | g | sham surgical control condition (for 6 hours) | 98756 | sham surgical control condition (for 6 hours) | | | | | | | | |

6 | body weight | SD | male | 267 | g | artificial aortocaval fistula (for 12 hours) | 98771 | artificial aortocaval fistula (for 12 hours) | | | | | | | | |

6 | body weight | SD | male | 271 | g | sham surgical control condition (for 12 hours) | 98772 | sham surgical control condition (for 12 hours) | | | | | | | | |

6 | body weight | SD | male | 291 | g | artificial aortocaval fistula (for 2 days) | 98773 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

6 | body weight | SD | male | 282 | g | sham surgical control condition (for 2 days) | 98774 | sham surgical control condition (for 2 days) | | | | | | | | |

6 | body weight | SD | male | 281 | g | artificial aortocaval fistula (for 5 days) | 98775 | artificial aortocaval fistula (for 5 days) | | | | | | | | |

6 | body weight | SD | male | 284 | g | sham surgical control condition (between 120 and 12 hours) | 98776 | sham surgical control condition (between 120 and 12 hours) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.3 | g/kg | artificial aortocaval fistula (for 6 hours) | 98777 | artificial aortocaval fistula (for 6 hours) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.3 | g/kg | sham surgical control condition (for 6 hours) | 98778 | sham surgical control condition (for 6 hours) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.5 | g/kg | artificial aortocaval fistula (for 12 hours) | 98779 | artificial aortocaval fistula (for 12 hours) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.4 | g/kg | sham surgical control condition (for 12 hours) | 98780 | sham surgical control condition (for 12 hours) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.9 | g/kg | artificial aortocaval fistula (for 2 days) | 98781 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.3 | g/kg | sham surgical control condition (for 2 days) | 98782 | sham surgical control condition (for 2 days) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 4.2 | g/kg | artificial aortocaval fistula (for 5 days) | 98783 | artificial aortocaval fistula (for 5 days) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.4 | g/kg | sham surgical control condition (between 120 and 12 hours) | 98784 | sham surgical control condition (between 120 and 12 hours) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.2 | mg/g | artificial aortocaval fistula (for 6 hours) | 98785 | artificial aortocaval fistula (for 6 hours) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.2 | mg/g | sham surgical control condition (for 6 hours) | 98786 | sham surgical control condition (for 6 hours) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.3 | mg/g | artificial aortocaval fistula (for 12 hours) | 98787 | artificial aortocaval fistula (for 12 hours) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.3 | mg/g | sham surgical control condition (for 12 hours) | 98788 | sham surgical control condition (for 12 hours) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.6 | mg/g | artificial aortocaval fistula (for 2 days) | 98789 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.2 | mg/g | sham surgical control condition (for 2 days) | 98790 | sham surgical control condition (for 2 days) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.7 | mg/g | artificial aortocaval fistula (for 5 days) | 98791 | artificial aortocaval fistula (for 5 days) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.3 | mg/g | sham surgical control condition (between 120 and 12 hours) | 98792 | sham surgical control condition (between 120 and 12 hours) | | | | | | | | |

6 | heart rate | SD | male | 436 | beats/min | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98793 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 385 | beats/min | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98794 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart rate | SD | male | 419 | beats/min | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98795 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 395 | beats/min | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98796 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart rate | SD | male | 405 | beats/min | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98797 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 389 | beats/min | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98798 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 395 | beats/min | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98799 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart rate | SD | male | 365 | beats/min | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98800 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart rate | SD | male | 420 | beats/min | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98801 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | heart rate | SD | male | 380 | beats/min | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98802 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | heart rate | SD | male | 378 | beats/min | artificial aortocaval fistula (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) then xylazine (10 mg/kg) and ketamine (80 mg/kg) (for 0 hours) | 98803 | artificial aortocaval fistula (for 2 days) | | | metoprolol succinate (100 mg/kg/d) (for 2 days) | | | xylazine (10 mg/kg) | ketamine (80 mg/kg) (for 0 hours) | |

N/A | heart rate | SD | male | 0 | beats/min | artificial aortocaval fistula (for 2 days) | 98804 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

6 | heart rate | SD | male | 365 | beats/min | sham surgical control condition (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98805 | sham surgical control condition (for 2 days) | | | metoprolol succinate (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | mean arterial blood pressure | SD | male | 85 | mmHg | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98806 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | mean arterial blood pressure | SD | male | 103 | mmHg | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98807 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | mean arterial blood pressure | SD | male | 70 | mmHg | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98808 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | mean arterial blood pressure | SD | male | 90 | mmHg | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98809 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | mean arterial blood pressure | SD | male | 71 | mmHg | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98810 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | mean arterial blood pressure | SD | male | 76 | mmHg | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98811 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | mean arterial blood pressure | SD | male | 74 | mmHg | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98812 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | mean arterial blood pressure | SD | male | 85 | mmHg | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98813 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | mean arterial blood pressure | SD | male | 72 | mmHg | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98814 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | mean arterial blood pressure | SD | male | 86 | mmHg | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98815 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | mean arterial blood pressure | SD | male | 71 | mmHg | artificial aortocaval fistula (for 2 days) then metoprolol (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98816 | artificial aortocaval fistula (for 2 days) | | | metoprolol (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | mean arterial blood pressure | SD | male | 82 | mmHg | sham surgical control condition (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98817 | sham surgical control condition (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | left ventricular end-diastolic blood pressure | SD | male | 7 | mmHg | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98818 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 5 | mmHg | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98819 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 5 | mmHg | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98820 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 2 | mmHg | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98821 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 6 | mmHg | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98822 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 2 | mmHg | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98823 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 7 | mmHg | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98824 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 2 | mmHg | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98825 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | left ventricular end-diastolic blood pressure | SD | male | 13 | mmHg | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98826 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | left ventricular end-diastolic blood pressure | SD | male | 3 | mmHg | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98827 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | left ventricular end-diastolic blood pressure | SD | male | 8 | mmHg | artificial aortocaval fistula (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98828 | artificial aortocaval fistula (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | left ventricular end-diastolic blood pressure | SD | male | 3 | mmHg | sham surgical control condition (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98829 | sham surgical control condition (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | left ventricular end-systolic blood pressure | SD | male | 72 | mmHg | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98830 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 58 | mmHg | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98831 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 61 | mmHg | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98832 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 62 | mmHg | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98833 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 56 | mmHg | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98834 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 66 | mmHg | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98835 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 71 | mmHg | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98836 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 58 | mmHg | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98837 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | left ventricular end-systolic blood pressure | SD | male | 56 | mmHg | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98838 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | left ventricular end-systolic blood pressure | SD | male | 64 | mmHg | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98839 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | left ventricular end-systolic blood pressure | SD | male | 57 | mmHg | artificial aortocaval fistula (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98840 | artificial aortocaval fistula (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | left ventricular end-systolic blood pressure | SD | male | 64 | mmHg | sham surgical control condition (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98841 | sham surgical control condition (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.4 | mm | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98842 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.2 | mm | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98843 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.8 | mm | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98844 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.3 | mm | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98845 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 8.1 | mm | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98846 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.1 | mm | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98847 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.9 | mm | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98848 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricular end-diastolic diameter | SD | male | 7.1 | mm | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98849 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 3.8 | mm | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98850 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 4.2 | mm | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98851 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 4.1 | mm | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98852 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 3.8 | mm | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98853 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 4.1 | mm | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98854 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 4 | mm | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98855 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 4.1 | mm | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98856 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-systolic diameter | SD | male | 3.9 | mm | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98857 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.4 | mm | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98858 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.6 | mm | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98859 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.4 | mm | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98860 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.6 | mm | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98861 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.3 | mm | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98862 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.6 | mm | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98863 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.5 | mm | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98864 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic posterior wall thickness | SD | male | 1.6 | mm | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98865 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.1 | | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98866 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.4 | | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98867 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.2 | | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98868 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.5 | | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98869 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.9 | | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98870 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.6 | | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98871 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.3 | | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98872 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.4 | | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98873 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.6 | mg/g | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) | 98874 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.3 | mg/g | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) | 98875 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.8 | mg/g | artificial aortocaval fistula (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) | 98876 | artificial aortocaval fistula (for 2 days) | | | metoprolol succinate (100 mg/kg/d) (for 2 days) | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 2.5 | mg/g | sham surgical control condition (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) | 98877 | sham surgical control condition (for 2 days) | | | metoprolol succinate (100 mg/kg/d) (for 2 days) | | | | | |

6 | ejection fraction | SD | male | 65 | % | artificial aortocaval fistula (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98878 | artificial aortocaval fistula (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | ejection fraction | SD | male | 65 | % | sham surgical control condition (for 6 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98879 | sham surgical control condition (for 6 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | ejection fraction | SD | male | 66 | % | artificial aortocaval fistula (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98880 | artificial aortocaval fistula (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | ejection fraction | SD | male | 63 | % | sham surgical control condition (for 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98881 | sham surgical control condition (for 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | ejection fraction | SD | male | 75 | % | artificial aortocaval fistula (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98882 | artificial aortocaval fistula (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | ejection fraction | SD | male | 65 | % | sham surgical control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98883 | sham surgical control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | ejection fraction | SD | male | 75 | % | artificial aortocaval fistula (for 5 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98884 | artificial aortocaval fistula (for 5 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | | | | |

6 | ejection fraction | SD | male | 64 | % | sham surgical control condition (between 120 and 12 hours) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98885 | sham surgical control condition (between 120 and 12 hours) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | | | | |

6 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8259 | mmHg/s | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98886 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8231 | mmHg/s | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98887 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | maximum rate of positive change in left ventricular blood pressure | SD | male | 6971 | mmHg/s | artificial aortocaval fistula (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98888 | artificial aortocaval fistula (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | maximum rate of positive change in left ventricular blood pressure | SD | male | 7985 | mmHg/s | sham surgical control condition (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98889 | sham surgical control condition (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | maximum rate of negative change in left ventricular blood pressure | SD | male | -6032 | mmHg/s | artificial aortocaval fistula (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98890 | artificial aortocaval fistula (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7197 | mmHg/s | sham surgical control condition (for 2 days) then vehicle control condition (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) | 98891 | sham surgical control condition (for 2 days) | | | vehicle control condition (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) | |

6 | maximum rate of negative change in left ventricular blood pressure | SD | male | -5661 | mmHg/s | artificial aortocaval fistula (for 2 days) then metoprolol (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98892 | artificial aortocaval fistula (for 2 days) | | | metoprolol (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

6 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7212 | mmHg/s | sham surgical control condition (for 2 days) then metoprolol succinate (100 mg/kg/d) (for 2 days) then ketamine (80 mg/kg) (for 0 hours) and xylazine (10 mg/kg) (for 0 hours) | 98893 | sham surgical control condition (for 2 days) | | | metoprolol succinate (100 mg/kg/d) (for 2 days) | | | ketamine (80 mg/kg) (for 0 hours) | xylazine (10 mg/kg) (for 0 hours) | |

7 | body weight | SD | male | 257 | g | left nephrectomy then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) | 98926 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (40 mg/kg) |

9 | body weight | SD | male | 258 | g | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) | 98927 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 256 | g | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) | 98928 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 301 | g | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) | 98929 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (40 mg/kg) |

9 | body weight | SD | male | 300 | g | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) | 98930 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 296 | g | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) | 98931 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 318 | g | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) | 98932 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (40 mg/kg) |

9 | body weight | SD | male | 308 | g | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) | 98933 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 386 | g | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) | 98934 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 267 | g | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) | 98935 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (40 mg/kg) |

9 | body weight | SD | male | 281 | g | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) | 98936 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (40 mg/kg) |

7 | body weight | SD | male | 346 | g | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) | 98937 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (40 mg/kg) |

7 | mean arterial blood pressure | SD | male | 115 | mmHg | left nephrectomy then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98938 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | mean arterial blood pressure | SD | male | 113 | mmHg | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98939 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 111 | mmHg | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98940 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 143 | mmHg | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98941 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | mean arterial blood pressure | SD | male | 148 | mmHg | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98942 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 148 | mmHg | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98943 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 161 | mmHg | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98944 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | mean arterial blood pressure | SD | male | 153 | mmHg | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98945 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 155 | mmHg | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98946 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 137 | mmHg | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98947 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | mean arterial blood pressure | SD | male | 129 | mmHg | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98948 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | mean arterial blood pressure | SD | male | 137 | mmHg | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98949 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 0.3 | mg/d | left nephrectomy then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98950 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine total protein excretion rate | SD | male | 0.7 | mg/d | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98951 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 0.9 | mg/d | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98952 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 29.3 | mg/d | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98953 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine total protein excretion rate | SD | male | 24 | mg/d | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98954 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 30 | mg/d | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98955 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 78 | mg/d | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98956 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine total protein excretion rate | SD | male | 74 | mg/d | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98957 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 97 | mg/d | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98958 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 70 | mg/d | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98959 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine total protein excretion rate | SD | male | 78 | mg/d | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98960 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine total protein excretion rate | SD | male | 127 | mg/d | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98961 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 0.06 | | left nephrectomy then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98962 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine protein level to urine creatinine level ratio | SD | male | 0.1 | | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98963 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 0.1 | | left nephrectomy then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98964 | left nephrectomy | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 3.5 | | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98965 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine protein level to urine creatinine level ratio | SD | male | 3.4 | | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98966 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 4.8 | | left nephrectomy (for 28 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98967 | left nephrectomy (for 28 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 7.6 | | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98968 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine protein level to urine creatinine level ratio | SD | male | 6.4 | | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98969 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 7.2 | | left nephrectomy (for 56 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98970 | left nephrectomy (for 56 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 14.4 | | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98971 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

9 | urine protein level to urine creatinine level ratio | SD | male | 13.6 | | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98972 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | urine protein level to urine creatinine level ratio | SD | male | 13.3 | | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (80 mg/kg) | 98973 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (80 mg/kg) |

7 | serum creatinine level | SD | male | 2.3 | mg/dl | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (40 mg/kg) | 98991 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (40 mg/kg) |

7 | serum creatinine level | SD | male | 2.5 | mg/dl | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (40 mg/kg) | 98992 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (40 mg/kg) |

7 | serum creatinine level | SD | male | 0.8 | mg/dl | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) | 98993 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (40 mg/kg) |

7 | creatinine clearance | SD | male | 0.44 | ml/min | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) then puromycin (80 mg/kg) | 98994 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-Shiga toxin 1 beta monoclonal antibody 13C4 (5 mg/kg) | | puromycin (80 mg/kg) |

7 | creatinine clearance | SD | male | 0.7 | ml/min | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (5 mg/kg) then puromycin (80 mg/kg) | 98995 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (5 mg/kg) | | puromycin (80 mg/kg) |

7 | creatinine clearance | SD | male | 1.34 | ml/min | left nephrectomy (for 70 days) then puromycin (100 mg/kg) then anti-transforming growth factor beta antibody (0.5 mg/kg) then puromycin (40 mg/kg) | 98996 | left nephrectomy (for 70 days) | | | puromycin (100 mg/kg) | | | anti-transforming growth factor beta antibody (0.5 mg/kg) | | puromycin (40 mg/kg) |

8 | body weight | SD | male | 359 | g | sham surgical control condition (for 28 days) | 99191 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | body weight | SD | male | 354 | g | artificial aortocaval fistula (for 28 days) | 99192 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | body weight | SD | male | 471 | g | sham surgical control condition (for 105 days) | 99193 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | body weight | SD | male | 489 | g | artificial aortocaval fistula (for 105 days) | 99194 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart weight | SD | male | 0.98 | g | sham surgical control condition (for 28 days) | 99195 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart weight | SD | male | 1.55 | g | artificial aortocaval fistula (for 28 days) | 99196 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart weight | SD | male | 1.26 | g | sham surgical control condition (for 105 days) | 99197 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart weight | SD | male | 2.23 | g | artificial aortocaval fistula (for 105 days) | 99198 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart weight to body weight ratio | SD | male | 2.7 | g/kg | sham surgical control condition (for 28 days) | 99199 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart weight to body weight ratio | SD | male | 4.4 | g/kg | artificial aortocaval fistula (for 28 days) | 99200 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart weight to body weight ratio | SD | male | 2.7 | g/kg | sham surgical control condition (for 105 days) | 99201 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart weight to body weight ratio | SD | male | 4.8 | g/kg | artificial aortocaval fistula (for 105 days) | 99202 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle weight to body weight ratio | SD | male | 2.1 | mg/g | sham surgical control condition (for 28 days) | 99203 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle weight to body weight ratio | SD | male | 3.1 | mg/g | artificial aortocaval fistula (for 28 days) | 99204 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart left ventricle weight to body weight ratio | SD | male | 1.9 | mg/g | sham surgical control condition (for 105 days) | 99205 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle weight to body weight ratio | SD | male | 3.1 | mg/g | artificial aortocaval fistula (for 105 days) | 99206 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart right ventricle weight to body weight ratio | SD | male | 0.5 | mg/g | sham surgical control condition (for 28 days) | 99207 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart right ventricle weight to body weight ratio | SD | male | 0.9 | mg/g | artificial aortocaval fistula (for 28 days) | 99208 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart right ventricle weight to body weight ratio | SD | male | 0.5 | mg/g | sham surgical control condition (for 105 days) | 99209 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart right ventricle weight to body weight ratio | SD | male | 1 | mg/g | artificial aortocaval fistula (for 105 days) | 99210 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | lung weight | SD | male | 1.46 | g | sham surgical control condition (for 28 days) | 99211 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | lung weight | SD | male | 1.84 | g | artificial aortocaval fistula (for 28 days) | 99212 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | lung weight | SD | male | 1.97 | g | sham surgical control condition (for 105 days) | 99213 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | lung weight | SD | male | 2.44 | g | artificial aortocaval fistula (for 105 days) | 99214 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart rate | SD | male | 260 | beats/min | sham surgical control condition (for 28 days) | 99215 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart rate | SD | male | 271 | beats/min | artificial aortocaval fistula (for 28 days) | 99216 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart rate | SD | male | 217 | beats/min | sham surgical control condition (for 105 days) | 99217 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart rate | SD | male | 220 | beats/min | artificial aortocaval fistula (for 105 days) | 99218 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | mean arterial blood pressure | SD | male | 114 | mmHg | sham surgical control condition (for 28 days) | 99219 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | mean arterial blood pressure | SD | male | 95 | mmHg | artificial aortocaval fistula (for 28 days) | 99220 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | mean arterial blood pressure | SD | male | 95 | mmHg | sham surgical control condition (for 105 days) | 99221 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | mean arterial blood pressure | SD | male | 82 | mmHg | artificial aortocaval fistula (for 105 days) | 99222 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | left ventricular end-diastolic blood pressure | SD | male | 2 | mmHg | sham surgical control condition (for 28 days) | 99223 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricular end-diastolic blood pressure | SD | male | 7 | mmHg | artificial aortocaval fistula (for 28 days) | 99224 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | left ventricular end-diastolic blood pressure | SD | male | 5 | mmHg | sham surgical control condition (for 105 days) | 99225 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | left ventricular end-diastolic blood pressure | SD | male | 9 | mmHg | artificial aortocaval fistula (for 105 days) | 99226 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8031 | mmHg/s | sham surgical control condition (for 28 days) | 99227 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8947 | mmHg/s | artificial aortocaval fistula (for 28 days) | 99228 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | maximum rate of positive change in left ventricular blood pressure | SD | male | 7529 | mmHg/s | sham surgical control condition (for 105 days) | 99229 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | maximum rate of positive change in left ventricular blood pressure | SD | male | 6600 | mmHg/s | artificial aortocaval fistula (for 105 days) | 99230 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7479 | mmHg/s | sham surgical control condition (for 28 days) | 99231 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | maximum rate of negative change in left ventricular blood pressure | SD | male | -6995 | mmHg/s | artificial aortocaval fistula (for 28 days) | 99232 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | maximum rate of negative change in left ventricular blood pressure | SD | male | -5401 | mmHg/s | sham surgical control condition (for 105 days) | 99233 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | maximum rate of negative change in left ventricular blood pressure | SD | male | -4244 | mmHg/s | artificial aortocaval fistula (for 105 days) | 99234 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricular end-diastolic diameter | SD | male | 7 | mm | sham surgical control condition (for 28 days) | 99235 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricular end-diastolic diameter | SD | male | 10.1 | mm | artificial aortocaval fistula (for 28 days) | 99236 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart left ventricular end-diastolic diameter | SD | male | 9 | mm | sham surgical control condition (for 105 days) | 99237 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricular end-diastolic diameter | SD | male | 11.6 | mm | artificial aortocaval fistula (for 105 days) | 99238 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle end-systolic diameter | SD | male | 4.3 | mm | sham surgical control condition (for 28 days) | 99239 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle end-systolic diameter | SD | male | 6.3 | mm | artificial aortocaval fistula (for 28 days) | 99240 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart left ventricle end-systolic diameter | SD | male | 5.6 | mm | sham surgical control condition (for 105 days) | 99241 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle end-systolic diameter | SD | male | 7.4 | mm | artificial aortocaval fistula (for 105 days) | 99242 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.8 | | sham surgical control condition (for 28 days) | 99243 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 7.7 | | artificial aortocaval fistula (for 28 days) | 99244 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.9 | | sham surgical control condition (for 105 days) | 99245 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 7.9 | | artificial aortocaval fistula (for 105 days) | 99246 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | left ventricle end-diastolic wall stress | SD | male | 3 | g/cm2 | sham surgical control condition (for 28 days) | 99247 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricle end-diastolic wall stress | SD | male | 14 | g/cm2 | artificial aortocaval fistula (for 28 days) | 99248 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | left ventricle end-diastolic wall stress | SD | male | 7 | g/cm2 | sham surgical control condition (for 105 days) | 99249 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | left ventricle end-diastolic wall stress | SD | male | 16 | g/cm2 | artificial aortocaval fistula (for 105 days) | 99250 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | left ventricle end-systolic wall stress | SD | male | 67 | g/cm2 | sham surgical control condition (for 28 days) | 99251 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricle end-systolic wall stress | SD | male | 77 | g/cm2 | artificial aortocaval fistula (for 28 days) | 99252 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | left ventricle end-systolic wall stress | SD | male | 72 | g/cm2 | sham surgical control condition (for 105 days) | 99253 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | left ventricle end-systolic wall stress | SD | male | 80 | g/cm2 | artificial aortocaval fistula (for 105 days) | 99254 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle fractional shortening | SD | male | 38 | % | sham surgical control condition (for 28 days) | 99255 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle fractional shortening | SD | male | 38 | % | artificial aortocaval fistula (for 28 days) | 99256 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

10 | heart left ventricle fractional shortening | SD | male | 40 | % | sham surgical control condition (for 105 days) | 99257 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle fractional shortening | SD | male | 34 | % | artificial aortocaval fistula (for 105 days) | 99258 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle interstitial angiotensin II level during a period of time | SD | male | 1.5 | pg/hr | sham surgical control condition (for 28 days) | 99259 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | heart left ventricle interstitial angiotensin II level during a period of time | SD | male | 3 | pg/hr | artificial aortocaval fistula (for 28 days) | 99260 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | heart left ventricle interstitial angiotensin II level during a period of time | SD | male | 1.6 | pg/hr | sham surgical control condition (for 105 days) | 99261 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle interstitial angiotensin II level during a period of time | SD | male | 1.9 | pg/hr | artificial aortocaval fistula (for 105 days) | 99262 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle interstitial bradykinin level during a period of time | SD | male | 6.4 | pg/hr | sham surgical control condition (for 28 days) | 99263 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | heart left ventricle interstitial bradykinin level during a period of time | SD | male | 9.3 | pg/hr | artificial aortocaval fistula (for 28 days) | 99264 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | heart left ventricle interstitial bradykinin level during a period of time | SD | male | 7.4 | pg/hr | sham surgical control condition (for 105 days) | 99265 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle interstitial bradykinin level during a period of time | SD | male | 12.4 | pg/hr | artificial aortocaval fistula (for 105 days) | 99266 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle interstitial norepinephrine level during a period of time | SD | male | 6.2 | pg/hr | sham surgical control condition (for 28 days) | 99267 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | heart left ventricle interstitial norepinephrine level during a period of time | SD | male | 6.8 | pg/hr | artificial aortocaval fistula (for 28 days) | 99268 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | heart left ventricle interstitial norepinephrine level during a period of time | SD | male | 5.9 | pg/hr | sham surgical control condition (for 105 days) | 99269 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle interstitial norepinephrine level during a period of time | SD | male | 10.2 | pg/hr | artificial aortocaval fistula (for 105 days) | 99270 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | heart left ventricle interstitial epinephrine level during a period of time | SD | male | 3.5 | pg/hr | sham surgical control condition (for 28 days) | 99271 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | heart left ventricle interstitial epinephrine level during a period of time | SD | male | 5.3 | pg/hr | artificial aortocaval fistula (for 28 days) | 99272 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | heart left ventricle interstitial epinephrine level during a period of time | SD | male | 3.5 | pg/hr | sham surgical control condition (for 105 days) | 99273 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | heart left ventricle interstitial epinephrine level during a period of time | SD | male | 8.6 | pg/hr | artificial aortocaval fistula (for 105 days) | 99274 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | plasma angiotensin II level | SD | male | 29 | pg/ml | sham surgical control condition (for 28 days) | 99275 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | plasma angiotensin II level | SD | male | 107 | pg/ml | artificial aortocaval fistula (for 28 days) | 99276 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | plasma angiotensin II level | SD | male | 34 | pg/ml | sham surgical control condition (for 105 days) | 99277 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | plasma angiotensin II level | SD | male | 65 | pg/ml | artificial aortocaval fistula (for 105 days) | 99278 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | plasma bradykinin level | SD | male | 10 | pg/ml | sham surgical control condition (for 28 days) | 99279 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | plasma bradykinin level | SD | male | 28 | pg/ml | artificial aortocaval fistula (for 28 days) | 99280 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | plasma bradykinin level | SD | male | 17 | pg/ml | sham surgical control condition (for 105 days) | 99281 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | plasma bradykinin level | SD | male | 29 | pg/ml | artificial aortocaval fistula (for 105 days) | 99282 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | plasma norepinephrine level | SD | male | 93 | pg/ml | sham surgical control condition (for 28 days) | 99283 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | plasma norepinephrine level | SD | male | 89 | pg/ml | artificial aortocaval fistula (for 28 days) | 99284 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | plasma norepinephrine level | SD | male | 102 | pg/ml | sham surgical control condition (for 105 days) | 99285 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | plasma norepinephrine level | SD | male | 159 | pg/ml | artificial aortocaval fistula (for 105 days) | 99286 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

8 | plasma epinephrine level | SD | male | 83 | pg/ml | sham surgical control condition (for 28 days) | 99287 | sham surgical control condition (for 28 days) | | | | | | | | |

9 | plasma epinephrine level | SD | male | 91 | pg/ml | artificial aortocaval fistula (for 28 days) | 99288 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | plasma epinephrine level | SD | male | 75 | pg/ml | sham surgical control condition (for 105 days) | 99289 | sham surgical control condition (for 105 days) | | | | | | | | |

10 | plasma epinephrine level | SD | male | 101 | pg/ml | artificial aortocaval fistula (for 105 days) | 99290 | artificial aortocaval fistula (for 105 days) | | | | | | | | |

5 | heart rate | SD | male | 359 | beats/min | sham surgical control condition (for 2 days) | 99291 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | heart rate | SD | male | 367 | beats/min | artificial aortocaval fistula (for 2 days) | 99292 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | heart rate | SD | male | 371 | beats/min | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99293 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | heart rate | SD | male | 375 | beats/min | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99294 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | heart rate | SD | male | 321 | beats/min | sham surgical control condition (for 28 days) | 99295 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart rate | SD | male | 307 | beats/min | artificial aortocaval fistula (for 28 days) | 99296 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | heart rate | SD | male | 312 | beats/min | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99297 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | heart rate | SD | male | 316 | beats/min | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99298 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | mean arterial blood pressure | SD | male | 100 | mmHg | sham surgical control condition (for 2 days) | 99299 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | mean arterial blood pressure | SD | male | 89 | mmHg | artificial aortocaval fistula (for 2 days) | 99300 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | mean arterial blood pressure | SD | male | 106 | mmHg | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99301 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | mean arterial blood pressure | SD | male | 84 | mmHg | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99302 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | mean arterial blood pressure | SD | male | 107 | mmHg | sham surgical control condition (for 28 days) | 99303 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | mean arterial blood pressure | SD | male | 90 | mmHg | artificial aortocaval fistula (for 28 days) | 99304 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | mean arterial blood pressure | SD | male | 106 | mmHg | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99305 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | mean arterial blood pressure | SD | male | 86 | mmHg | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99306 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | left ventricular end-diastolic blood pressure | SD | male | 6 | mmHg | sham surgical control condition (for 2 days) | 99307 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | left ventricular end-diastolic blood pressure | SD | male | 11 | mmHg | artificial aortocaval fistula (for 2 days) | 99308 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | left ventricular end-diastolic blood pressure | SD | male | 5 | mmHg | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99309 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | left ventricular end-diastolic blood pressure | SD | male | 11 | mmHg | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99310 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | left ventricular end-diastolic blood pressure | SD | male | 4.2 | mmHg | sham surgical control condition (for 28 days) | 99311 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricular end-diastolic blood pressure | SD | male | 10 | mmHg | artificial aortocaval fistula (for 28 days) | 99312 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | left ventricular end-diastolic blood pressure | SD | male | 4 | mmHg | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99313 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | left ventricular end-diastolic blood pressure | SD | male | 10 | mmHg | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99314 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | left ventricular end-systolic blood pressure | SD | male | 55 | mmHg | sham surgical control condition (for 2 days) | 99315 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | left ventricular end-systolic blood pressure | SD | male | 61 | mmHg | artificial aortocaval fistula (for 2 days) | 99316 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | left ventricular end-systolic blood pressure | SD | male | 58 | mmHg | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99317 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | left ventricular end-systolic blood pressure | SD | male | 57 | mmHg | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99318 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | left ventricular end-systolic blood pressure | SD | male | 85 | mmHg | sham surgical control condition (for 28 days) | 99319 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricular end-systolic blood pressure | SD | male | 75 | mmHg | artificial aortocaval fistula (for 28 days) | 99320 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | left ventricular end-systolic blood pressure | SD | male | 86 | mmHg | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99321 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | left ventricular end-systolic blood pressure | SD | male | 70 | mmHg | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99322 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8767 | mmHg/s | sham surgical control condition (for 2 days) | 99323 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | maximum rate of positive change in left ventricular blood pressure | SD | male | 9386 | mmHg/s | artificial aortocaval fistula (for 2 days) | 99324 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8301 | mmHg/s | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99325 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | maximum rate of positive change in left ventricular blood pressure | SD | male | 9065 | mmHg/s | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99326 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8505 | mmHg/s | sham surgical control condition (for 28 days) | 99327 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8116 | mmHg/s | artificial aortocaval fistula (for 28 days) | 99328 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | maximum rate of positive change in left ventricular blood pressure | SD | male | 7931 | mmHg/s | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99329 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | maximum rate of positive change in left ventricular blood pressure | SD | male | 8937 | mmHg/s | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99330 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7474 | mmHg/s | sham surgical control condition (for 2 days) | 99331 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | maximum rate of negative change in left ventricular blood pressure | SD | male | -8797 | mmHg/s | artificial aortocaval fistula (for 2 days) | 99332 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | maximum rate of negative change in left ventricular blood pressure | SD | male | -8474 | mmHg/s | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99333 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7879 | mmHg/s | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99334 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7379 | mmHg/s | sham surgical control condition (for 28 days) | 99335 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | maximum rate of negative change in left ventricular blood pressure | SD | male | -7422 | mmHg/s | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99336 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | maximum rate of negative change in left ventricular blood pressure | SD | male | -6834 | mmHg/s | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99337 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | maximum rate of negative change in left ventricular blood pressure | SD | male | -5948 | mmHg/s | artificial aortocaval fistula (for 28 days) | 99338 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

5 | heart left ventricular end-diastolic diameter | SD | male | 6.9 | mm | sham surgical control condition (for 2 days) | 99339 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | heart left ventricular end-diastolic diameter | SD | male | 8.2 | mm | artificial aortocaval fistula (for 2 days) | 99340 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | heart left ventricular end-diastolic diameter | SD | male | 7 | mm | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99341 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | heart left ventricular end-diastolic diameter | SD | male | 8 | mm | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99342 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | heart left ventricular end-diastolic diameter | SD | male | 7.7 | mm | sham surgical control condition (for 28 days) | 99343 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricular end-diastolic diameter | SD | male | 10.6 | mm | artificial aortocaval fistula (for 28 days) | 99344 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | heart left ventricular end-diastolic diameter | SD | male | 7.6 | mm | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99345 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | heart left ventricular end-diastolic diameter | SD | male | 10.2 | mm | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99346 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | heart left ventricle end-systolic diameter | SD | male | 4 | mm | sham surgical control condition (for 2 days) | 99347 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | heart left ventricle end-systolic diameter | SD | male | 4.3 | mm | artificial aortocaval fistula (for 2 days) | 99348 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | heart left ventricle end-systolic diameter | SD | male | 4.1 | mm | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99349 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | heart left ventricle end-systolic diameter | SD | male | 4 | mm | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99350 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | heart left ventricle end-systolic diameter | SD | male | 4.7 | mm | sham surgical control condition (for 28 days) | 99351 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle end-systolic diameter | SD | male | 6.8 | mm | artificial aortocaval fistula (for 28 days) | 99352 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | heart left ventricle end-systolic diameter | SD | male | 4.7 | mm | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99353 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | heart left ventricle end-systolic diameter | SD | male | 5.9 | mm | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99354 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.6 | | sham surgical control condition (for 2 days) | 99355 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.8 | | artificial aortocaval fistula (for 2 days) | 99356 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.6 | | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99357 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.4 | | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99358 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.2 | | sham surgical control condition (for 28 days) | 99359 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 5.7 | | artificial aortocaval fistula (for 28 days) | 99360 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 4.5 | | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99361 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | heart left ventricle end-diastolic diameter to posterior wall thickness ratio | SD | male | 6 | | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99362 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | heart left ventricle fractional shortening | SD | male | 41 | % | sham surgical control condition (for 2 days) | 99363 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | heart left ventricle fractional shortening | SD | male | 48 | % | artificial aortocaval fistula (for 2 days) | 99364 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | heart left ventricle fractional shortening | SD | male | 43 | % | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99365 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | heart left ventricle fractional shortening | SD | male | 50 | % | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99366 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | heart left ventricle fractional shortening | SD | male | 38 | % | sham surgical control condition (for 28 days) | 99367 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | heart left ventricle fractional shortening | SD | male | 37 | % | artificial aortocaval fistula (for 28 days) | 99368 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | heart left ventricle fractional shortening | SD | male | 39 | % | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99369 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | heart left ventricle fractional shortening | SD | male | 43 | % | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99370 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | ejection fraction | SD | male | 66 | % | sham surgical control condition (for 2 days) | 99371 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | ejection fraction | SD | male | 76 | % | artificial aortocaval fistula (for 2 days) | 99372 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | ejection fraction | SD | male | 72 | % | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99373 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | ejection fraction | SD | male | 79 | % | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99374 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | ejection fraction | SD | male | 66 | % | sham surgical control condition (for 28 days) | 99375 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | ejection fraction | SD | male | 63 | % | artificial aortocaval fistula (for 28 days) | 99376 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | ejection fraction | SD | male | 67 | % | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99377 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | ejection fraction | SD | male | 71 | % | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99378 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | left ventricle end-diastolic wall stress | SD | male | 4 | g/cm2 | sham surgical control condition (for 2 days) | 99387 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | left ventricle end-diastolic wall stress | SD | male | 16 | g/cm2 | artificial aortocaval fistula (for 2 days) | 99388 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | left ventricle end-diastolic wall stress | SD | male | 6 | g/cm2 | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99389 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | left ventricle end-diastolic wall stress | SD | male | 16 | g/cm2 | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99390 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | left ventricle end-diastolic wall stress | SD | male | 4 | g/cm2 | sham surgical control condition (for 28 days) | 99391 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricle end-diastolic wall stress | SD | male | 15 | g/cm2 | artificial aortocaval fistula (for 28 days) | 99392 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | left ventricle end-diastolic wall stress | SD | male | 4 | g/cm2 | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99393 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | left ventricle end-diastolic wall stress | SD | male | 16 | g/cm2 | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99394 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | left ventricle end-systolic wall stress | SD | male | 50 | g/cm2 | sham surgical control condition (for 2 days) | 99395 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | left ventricle end-systolic wall stress | SD | male | 54 | g/cm2 | artificial aortocaval fistula (for 2 days) | 99396 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | left ventricle end-systolic wall stress | SD | male | 49 | g/cm2 | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99397 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | left ventricle end-systolic wall stress | SD | male | 37 | g/cm2 | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99398 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | left ventricle end-systolic wall stress | SD | male | 65 | g/cm2 | sham surgical control condition (for 28 days) | 99399 | sham surgical control condition (for 28 days) | | | | | | | | |

8 | left ventricle end-systolic wall stress | SD | male | 81 | g/cm2 | artificial aortocaval fistula (for 28 days) | 99400 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

7 | left ventricle end-systolic wall stress | SD | male | 68 | g/cm2 | sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99401 | sham surgical control condition (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | left ventricle end-systolic wall stress | SD | male | 62 | g/cm2 | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99402 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

5 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 3.9 | % | sham surgical control condition (for 2 days) | 99403 | sham surgical control condition (for 2 days) | | | | | | | | |

5 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 2.1 | % | artificial aortocaval fistula (for 2 days) | 99404 | artificial aortocaval fistula (for 2 days) | | | | | | | | |

5 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 4 | % | sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99405 | sham surgical control condition (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

5 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 3.6 | % | artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days) | 99406 | artificial aortocaval fistula (for 2 days) | | | Aprotinin (12000 kIU) (for 2 days) | | | | | |

7 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 3.5 | % | sham surgical control condition (for 28 days) | 99407 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 2.4 | % | artificial aortocaval fistula (for 28 days) | 99408 | artificial aortocaval fistula (for 28 days) | | | | | | | | |

8 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 3.5 | % | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99409 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | ratio of the area occupied by interstitial collagen to the total area of the heart left ventricle | SD | male | 3.2 | % | artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days) | 99410 | artificial aortocaval fistula (for 28 days) | | | Aprotinin (12000 kIU) (for 28 days) | | | | | |

8 | body weight | SD | male | 526 | g | streptozotocin (60 mg/kg) then insulin | 99871 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | body weight | SD | male | 563 | g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99891 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | body weight | SD | male | 675 | g | naive control condition | 99892 | naive control condition | | | | | | | | |

8 | left kidney wet weight | SD | male | 1.94 | g | streptozotocin (60 mg/kg) then insulin | 99893 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | left kidney wet weight | SD | male | 1.9 | g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99894 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | left kidney wet weight | SD | male | 1.66 | g | naive control condition | 99895 | naive control condition | | | | | | | | |

8 | blood glucose level | SD | male | 334 | mg/dl | streptozotocin (60 mg/kg) then insulin | 99896 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | blood glucose level | SD | male | 343 | mg/dl | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99897 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | blood glucose level | SD | male | 106 | mg/dl | naive control condition | 99898 | naive control condition | | | | | | | | |

8 | systolic blood pressure | SD | male | 152 | mmHg | streptozotocin (60 mg/kg) then insulin | 99899 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | systolic blood pressure | SD | male | 128 | mmHg | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99900 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | systolic blood pressure | SD | male | 127 | mmHg | naive control condition | 99901 | naive control condition | | | | | | | | |

8 | glomerular filtration rate to body weight ratio | SD | male | 0.67 | ml/min/100g | streptozotocin (60 mg/kg) then insulin | 99902 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | glomerular filtration rate to body weight ratio | SD | male | 0.68 | ml/min/100g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99903 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | glomerular filtration rate to body weight ratio | SD | male | 0.67 | ml/min/100g | naive control condition | 99904 | naive control condition | | | | | | | | |

8 | effective renal plasma flow | SD | male | 2.28 | ml/min/100g | streptozotocin (60 mg/kg) then insulin | 99905 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | effective renal plasma flow | SD | male | 2.31 | ml/min/100g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99906 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | effective renal plasma flow | SD | male | 2.24 | ml/min/100g | naive control condition | 99907 | naive control condition | | | | | | | | |

8 | renal filtration fraction | SD | male | 0.3 | | streptozotocin (60 mg/kg) then insulin | 99911 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | renal filtration fraction | SD | male | 0.29 | | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99912 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | renal filtration fraction | SD | male | 0.3 | | naive control condition | 99913 | naive control condition | | | | | | | | |

8 | body weight | SD | male | 588 | g | streptozotocin (60 mg/kg) then insulin | 99914 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | body weight | SD | male | 570 | g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99915 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | body weight | SD | male | 738 | g | naive control condition | 99916 | naive control condition | | | | | | | | |

8 | left kidney wet weight | SD | male | 2.18 | g | streptozotocin (60 mg/kg) then insulin | 99917 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | left kidney wet weight | SD | male | 2.14 | g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99918 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | left kidney wet weight | SD | male | 1.83 | g | naive control condition | 99919 | naive control condition | | | | | | | | |

8 | blood glucose level | SD | male | 358 | mg/dl | streptozotocin (60 mg/kg) then insulin | 99920 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | blood glucose level | SD | male | 350 | mg/dl | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99921 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | blood glucose level | SD | male | 98 | mg/dl | naive control condition | 99922 | naive control condition | | | | | | | | |

8 | systolic blood pressure | SD | male | 150 | mmHg | streptozotocin (60 mg/kg) then insulin | 99923 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | systolic blood pressure | SD | male | 128 | mmHg | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99924 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | systolic blood pressure | SD | male | 126 | mmHg | naive control condition | 99925 | naive control condition | | | | | | | | |

8 | glomerular filtration rate to body weight ratio | SD | male | 0.67 | ml/min/100g | streptozotocin (60 mg/kg) then insulin | 99926 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | glomerular filtration rate to body weight ratio | SD | male | 0.65 | ml/min/100g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99927 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | glomerular filtration rate to body weight ratio | SD | male | 0.69 | ml/min/100g | naive control condition | 99928 | naive control condition | | | | | | | | |

8 | effective renal plasma flow | SD | male | 2.31 | ml/min/100g | streptozotocin (60 mg/kg) then insulin | 99929 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | effective renal plasma flow | SD | male | 2.27 | ml/min/100g | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99930 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | effective renal plasma flow | SD | male | 2.33 | ml/min/100g | naive control condition | 99931 | naive control condition | | | | | | | | |

8 | renal filtration fraction | SD | male | 0.29 | | streptozotocin (60 mg/kg) then insulin | 99932 | streptozotocin (60 mg/kg) | | | insulin | | | | | |

8 | renal filtration fraction | SD | male | 0.29 | | streptozotocin (60 mg/kg) then insulin then Moexipril (30~35 mg/kg/d) (for 112 days) | 99933 | streptozotocin (60 mg/kg) | | | insulin | | | Moexipril (30~35 mg/kg/d) (for 112 days) | | |

8 | renal filtration fraction | SD | male | 0.29 | | naive control condition | 99934 | naive control condition | | | | | | | | |

6 | systolic blood pressure | SD | male | 113.6 | mmHg | controlled content diet (1.2 %) (for 70 days) then controlled calcium content diet (1 %) (for 70 days) | 100112 | controlled content diet (1.2 %) (for 70 days) | | | controlled calcium content diet (1 %) (for 70 days) | | | | | |

6 | systolic blood pressure | SD | male | 142.8 | mmHg | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled calcium content diet (1 %) (for 70 days) | 100114 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled calcium content diet (1 %) (for 70 days) | | |

8 | systolic blood pressure | SD | male | 134.3 | mmHg | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled calcium content diet (1 %) (for 70 days) and paricalcitol (0.1 ug/kg) (for 70 days) | 100116 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled calcium content diet (1 %) (for 70 days) | paricalcitol (0.1 ug/kg) (for 70 days) | |

6 | systolic blood pressure | SD | male | 142.6 | mmHg | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled calcium content diet (1 %) (for 70 days) and paricalcitol (0.3 ug/kg) (for 70 days) | 100118 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled calcium content diet (1 %) (for 70 days) | paricalcitol (0.3 ug/kg) (for 70 days) | |

6 | blood glucose level | SD | male | 134.7 | mg/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100120 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | |

8 | blood glucose level | SD | male | 137.7 | mg/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.1 ug/kg) (for 70 days) | 100122 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.1 ug/kg) (for 70 days) | |

6 | blood glucose level | SD | male | 138.6 | mg/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.3 ug/kg) (for 70 days) | 100124 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.3 ug/kg) (for 70 days) | |

6 | blood hemoglobin A1c level | SD | male | 3.2 | % | controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100126 | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | | | | |

6 | blood hemoglobin A1c level | SD | male | 3.2 | % | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100128 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | |

8 | blood hemoglobin A1c level | SD | male | 3.2 | % | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.1 ug/kg) (for 70 days) | 100130 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.1 ug/kg) (for 70 days) | |

6 | blood hemoglobin A1c level | SD | male | 3.3 | % | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.3 ug/kg) (for 70 days) | 100132 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.3 ug/kg) (for 70 days) | |

6 | creatinine clearance | SD | male | 5.2 | ml/min | controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100134 | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | | | | |

6 | creatinine clearance | SD | male | 2.6 | ml/min | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100136 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | |

8 | creatinine clearance | SD | male | 2.3 | ml/min | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.1 ug/kg) (for 70 days) | 100138 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.1 ug/kg) (for 70 days) | |

6 | creatinine clearance | SD | male | 2.3 | ml/min | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.3 ug/kg) (for 70 days) | 100140 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.3 ug/kg) (for 70 days) | |

6 | blood urea nitrogen level | SD | male | 17.7 | mg/dl | controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100152 | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | | | | |

6 | blood urea nitrogen level | SD | male | 34.2 | mg/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100154 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | |

8 | blood urea nitrogen level | SD | male | 36.5 | mg/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.1 ug/kg) (for 70 days) | 100156 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.1 ug/kg) (for 70 days) | |

6 | blood urea nitrogen level | SD | male | 38.2 | mg/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.3 ug/kg) (for 70 days) | 100158 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.3 ug/kg) (for 70 days) | |

6 | blood albumin level | SD | male | 3.7 | g/dl | controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100160 | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | | | | |

6 | blood albumin level | SD | male | 3 | g/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) | 100162 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | | |

6 | blood albumin level | SD | male | 3.2 | g/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.3 ug/kg) (for 70 days) | 100165 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.3 ug/kg) (for 70 days) | |

7 | blood albumin level | SD | male | 3.1 | g/dl | nephrectomy then controlled content diet (1.2 %) (for 70 days) then controlled content diet (1 %) (for 70 days) and paricalcitol (0.1 ug/kg) (for 70 days) | 100166 | nephrectomy | | | controlled content diet (1.2 %) (for 70 days) | | | controlled content diet (1 %) (for 70 days) | paricalcitol (0.1 ug/kg) (for 70 days) | |

1 | systolic blood pressure | SD | male | 117 | mmHg | enalapril (5 ml/kg/d) (for 10 days) | 100178 | enalapril (5 ml/kg/d) (for 10 days) | | | | | | | | |

1 | systolic blood pressure | SD | male | 121 | mmHg | naive control condition | 100188 | naive control condition | | | | | | | | |

1 | systolic blood pressure | SD | male | 119 | mmHg | naive control condition | 100189 | naive control condition | | | | | | | | |

1 | systolic blood pressure | SD | male | 116 | mmHg | losartan (5 ml/kg/d) (for 10 days) | 100190 | losartan (5 ml/kg/d) (for 10 days) | | | | | | | | |

8 | body weight | SD | female | 305.4 | g | naive control condition | 100631 | naive control condition | | | | | | | | |

13 | body weight | SD | female | 283.6 | g | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100632 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | |

12 | body weight | SD | female | 281.9 | g | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then enalapril (25 mg/l) (for 90 days) | 100633 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | enalapril (25 mg/l) (for 90 days) | | | | | |

10 | body weight | SD | female | 291.9 | g | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) | 100634 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | | | | | |

12 | body weight | SD | female | 290.6 | g | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) and enalapril (25 mg/l) (for 90 days) | 100635 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | enalapril (25 mg/l) (for 90 days) | | | | |

8 | serum creatinine level | SD | female | 0.58 | mg/dl | naive control condition | 100636 | naive control condition | | | | | | | | |

13 | serum creatinine level | SD | female | 1.65 | mg/dl | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100637 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | |

12 | serum creatinine level | SD | female | 0.93 | mg/dl | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then enalapril (25 mg/l) (for 90 days) | 100638 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | enalapril (25 mg/l) (for 90 days) | | | | | |

10 | serum creatinine level | SD | female | 1.5 | mg/dl | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) | 100639 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | | | | | |

12 | serum creatinine level | SD | female | 0.93 | mg/dl | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) and enalapril (25 mg/l) (for 90 days) | 100640 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | enalapril (25 mg/l) (for 90 days) | | | | |

8 | creatinine clearance | SD | female | 0.96 | ml/min | naive control condition | 100641 | naive control condition | | | | | | | | |

13 | creatinine clearance | SD | female | 0.3 | ml/min | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100642 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | |

12 | creatinine clearance | SD | female | 0.56 | ml/min | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then enalapril (25 mg/l) (for 90 days) | 100643 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | enalapril (25 mg/l) (for 90 days) | | | | | |

10 | creatinine clearance | SD | female | 0.35 | ml/min | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) | 100644 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | | | | | |

12 | creatinine clearance | SD | female | 0.58 | ml/min | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) and enalapril (25 mg/l) (for 90 days) | 100645 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | enalapril (25 mg/l) (for 90 days) | | | | |

8 | serum parathyroid hormone level | SD | female | 83 | pg/ml | naive control condition | 100646 | naive control condition | | | | | | | | |

13 | serum parathyroid hormone level | SD | female | 3496 | pg/ml | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then vehicle control condition (100 ul) (for 90 days) | 100647 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | vehicle control condition (100 ul) (for 90 days) | | | | | |

12 | serum parathyroid hormone level | SD | female | 371 | pg/ml | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then enalapril (25 mg/l) (for 90 days) | 100648 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | enalapril (25 mg/l) (for 90 days) | | | | | |

10 | serum parathyroid hormone level | SD | female | 629 | pg/ml | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) | 100649 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | | | | | |

12 | serum parathyroid hormone level | SD | female | 170 | pg/ml | controlled calcium content diet (0.6 %) (for 97 days) and controlled content diet (0.9 %) (for 97 days) and unilateral nephrectomy (for 97 days) then paricalcitol (0.8 mg/kg) (for 90 days) and enalapril (25 mg/l) (for 90 days) | 100650 | controlled calcium content diet (0.6 %) (for 97 days) | controlled content diet (0.9 %) (for 97 days) | unilateral nephrectomy (for 97 days) | paricalcitol (0.8 mg/kg) (for 90 days) | enalapril (25 mg/l) (for 90 days) | | | | |

6 | body weight | SD | male | 403.2 | g | left anterior descending coronary artery occlusion (for 28 days) | 101075 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | body weight | SD | male | 378.1 | g | sham surgical control condition (for 28 days) | 101076 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | body weight | SD | male | 568.3 | g | left anterior descending coronary artery occlusion (for 140 days) | 101077 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | body weight | SD | male | 532.2 | g | sham surgical control condition (for 140 days) | 101078 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart weight | SD | male | 1.25 | g | left anterior descending coronary artery occlusion (for 28 days) | 101079 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart weight | SD | male | 1.13 | g | sham surgical control condition (for 28 days) | 101080 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart weight | SD | male | 1.57 | g | left anterior descending coronary artery occlusion (for 140 days) | 101081 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart weight | SD | male | 1.41 | g | sham surgical control condition (for 140 days) | 101082 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 3.09 | g/kg | left anterior descending coronary artery occlusion (for 28 days) | 101083 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 2.92 | g/kg | sham surgical control condition (for 28 days) | 101084 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart weight to body weight ratio | SD | male | 2.78 | g/kg | left anterior descending coronary artery occlusion (for 140 days) | 101085 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart weight to body weight ratio | SD | male | 2.66 | g/kg | sham surgical control condition (for 140 days) | 101086 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | systolic blood pressure | SD | male | 125 | mmHg | left anterior descending coronary artery occlusion (for 28 days) | 101087 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | systolic blood pressure | SD | male | 134 | mmHg | sham surgical control condition (for 28 days) | 101088 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | systolic blood pressure | SD | male | 143 | mmHg | left anterior descending coronary artery occlusion (for 140 days) | 101089 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | systolic blood pressure | SD | male | 144 | mmHg | sham surgical control condition (for 140 days) | 101090 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart left ventricle weight | SD | male | 0.67 | g | left anterior descending coronary artery occlusion (for 28 days) | 101091 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart left ventricle weight | SD | male | 0.6 | g | sham surgical control condition (for 28 days) | 101092 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart left ventricle weight | SD | male | 0.87 | g | left anterior descending coronary artery occlusion (for 140 days) | 101093 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart left ventricle weight | SD | male | 0.76 | g | sham surgical control condition (for 140 days) | 101094 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 1.67 | mg/g | left anterior descending coronary artery occlusion (for 28 days) | 101095 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 1.56 | mg/g | sham surgical control condition (for 28 days) | 101096 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart left ventricle weight to body weight ratio | SD | male | 1.53 | mg/g | left anterior descending coronary artery occlusion (for 140 days) | 101097 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart left ventricle weight to body weight ratio | SD | male | 1.44 | mg/g | sham surgical control condition (for 140 days) | 101098 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart right ventricle weight | SD | male | 0.25 | g | left anterior descending coronary artery occlusion (for 28 days) | 101099 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart right ventricle weight | SD | male | 0.23 | g | sham surgical control condition (for 28 days) | 101100 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart right ventricle weight | SD | male | 0.29 | g | left anterior descending coronary artery occlusion (for 140 days) | 101101 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart right ventricle weight | SD | male | 0.27 | g | sham surgical control condition (for 140 days) | 101102 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart right ventricle weight to body weight ratio | SD | male | 0.62 | mg/g | left anterior descending coronary artery occlusion (for 28 days) | 101103 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart right ventricle weight to body weight ratio | SD | male | 0.59 | mg/g | sham surgical control condition (for 28 days) | 101104 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart right ventricle weight to body weight ratio | SD | male | 0.52 | mg/g | left anterior descending coronary artery occlusion (for 140 days) | 101105 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart right ventricle weight to body weight ratio | SD | male | 0.51 | mg/g | sham surgical control condition (for 140 days) | 101106 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | left atrium weight | SD | male | 0.04 | g | left anterior descending coronary artery occlusion (for 28 days) | 101107 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | left atrium weight | SD | male | 0.03 | g | sham surgical control condition (for 28 days) | 101108 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | left atrium weight | SD | male | 0.05 | g | left anterior descending coronary artery occlusion (for 140 days) | 101109 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | left atrium weight | SD | male | 0.04 | g | sham surgical control condition (for 140 days) | 101110 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart left atrium weight to body weight ratio | SD | male | 0.1 | mg/g | left anterior descending coronary artery occlusion (for 28 days) | 101111 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart left atrium weight to body weight ratio | SD | male | 0.07 | mg/g | sham surgical control condition (for 28 days) | 101112 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart left atrium weight to body weight ratio | SD | male | 0.08 | mg/g | left anterior descending coronary artery occlusion (for 140 days) | 101113 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart left atrium weight to body weight ratio | SD | male | 0.08 | mg/g | sham surgical control condition (for 140 days) | 101114 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | right atrium weight | SD | male | 0.04 | g | left anterior descending coronary artery occlusion (for 28 days) | 101115 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | right atrium weight | SD | male | 0.04 | g | sham surgical control condition (for 28 days) | 101116 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | right atrium weight | SD | male | 0.05 | g | left anterior descending coronary artery occlusion (for 140 days) | 101117 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | right atrium weight | SD | male | 0.04 | g | sham surgical control condition (for 140 days) | 101118 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart right atrium weight to body weight ratio | SD | male | 0.11 | mg/g | left anterior descending coronary artery occlusion (for 28 days) | 101119 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart right atrium weight to body weight ratio | SD | male | 0.1 | mg/g | sham surgical control condition (for 28 days) | 101120 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart right atrium weight to body weight ratio | SD | male | 0.09 | mg/g | left anterior descending coronary artery occlusion (for 140 days) | 101121 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart right atrium weight to body weight ratio | SD | male | 0.08 | mg/g | sham surgical control condition (for 140 days) | 101122 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | heart septum weight | SD | male | 0.24 | g | left anterior descending coronary artery occlusion (for 28 days) | 101123 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

6 | heart septum weight | SD | male | 0.23 | g | sham surgical control condition (for 28 days) | 101124 | sham surgical control condition (for 28 days) | | | | | | | | |

10 | heart septum weight | SD | male | 0.33 | g | left anterior descending coronary artery occlusion (for 140 days) | 101125 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | heart septum weight | SD | male | 0.29 | g | sham surgical control condition (for 140 days) | 101126 | sham surgical control condition (for 140 days) | | | | | | | | |

6 | calculated heart left ventricle infarction area | SD | male | 35.4 | % | left anterior descending coronary artery occlusion (for 28 days) | 101127 | left anterior descending coronary artery occlusion (for 28 days) | | | | | | | | |

10 | calculated heart left ventricle infarction area | SD | male | 37.9 | % | left anterior descending coronary artery occlusion (for 140 days) | 101128 | left anterior descending coronary artery occlusion (for 140 days) | | | | | | | | |

6 | body weight | SD | male | 336 | g | sham surgical control condition (between 12 and 14 days) | 101535 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | body weight | SD | male | 277 | g | unilateral nephrectomy (between 12 and 14 days) | 101536 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | body weight | SD | male | 285 | g | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101537 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | body weight | SD | male | 302 | g | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101538 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | change in body weight | SD | male | 84 | g | sham surgical control condition (between 12 and 14 days) | 101539 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | change in body weight | SD | male | 66 | g | unilateral nephrectomy (between 12 and 14 days) | 101540 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | change in body weight | SD | male | 74 | g | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101541 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | change in body weight | SD | male | 66 | g | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101542 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | left kidney wet weight | SD | male | 1.11 | g | sham surgical control condition (between 12 and 14 days) | 101543 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | left kidney wet weight | SD | male | 1.37 | g | unilateral nephrectomy (between 12 and 14 days) | 101544 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | left kidney wet weight | SD | male | 1.16 | g | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101545 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | left kidney wet weight | SD | male | 1.49 | g | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101546 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | systolic blood pressure | SD | male | 118 | mmHg | sham surgical control condition (between 12 and 14 days) | 101547 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | systolic blood pressure | SD | male | 185 | mmHg | unilateral nephrectomy (between 12 and 14 days) | 101548 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | systolic blood pressure | SD | male | 125 | mmHg | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101549 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | systolic blood pressure | SD | male | 149 | mmHg | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101550 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | urine protein excretion rate | SD | male | 10 | mg/d | sham surgical control condition (between 12 and 14 days) | 101551 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | urine protein excretion rate | SD | male | 121 | mg/d | unilateral nephrectomy (between 12 and 14 days) | 101552 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | urine protein excretion rate | SD | male | 31 | mg/d | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101553 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | urine protein excretion rate | SD | male | 87 | mg/d | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101554 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | plasma aldosterone level | SD | male | 50 | pg/ml | sham surgical control condition (between 12 and 14 days) | 101555 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | plasma aldosterone level | SD | male | 526 | pg/ml | unilateral nephrectomy (between 12 and 14 days) | 101556 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | plasma aldosterone level | SD | male | 181 | pg/ml | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101557 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | plasma aldosterone level | SD | male | 487 | pg/ml | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101558 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | adrenal gland weight | SD | male | 51 | mg | sham surgical control condition (between 12 and 14 days) | 101559 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | adrenal gland weight | SD | male | 63 | mg | unilateral nephrectomy (between 12 and 14 days) | 101560 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | adrenal gland weight | SD | male | 56 | mg | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101561 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | adrenal gland weight | SD | male | 60 | mg | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101562 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | plasma renin activity level | SD | male | 3.1 | ng/ml/h | sham surgical control condition (between 12 and 14 days) | 101563 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | plasma renin activity level | SD | male | 4.3 | ng/ml/h | unilateral nephrectomy (between 12 and 14 days) | 101564 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | plasma renin activity level | SD | male | 13.3 | ng/ml/h | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101565 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | plasma renin activity level | SD | male | 5.2 | ng/ml/h | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101566 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | adrenal gland renin level | SD | male | 2.2 | ng/ml/h | sham surgical control condition (between 12 and 14 days) | 101567 | sham surgical control condition (between 12 and 14 days) | | | | | | | | |

11 | adrenal gland renin level | SD | male | 1.3 | ng/ml/h | unilateral nephrectomy (between 12 and 14 days) | 101568 | unilateral nephrectomy (between 12 and 14 days) | | | | | | | | |

5 | adrenal gland renin level | SD | male | 3.6 | ng/ml/h | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) | 101569 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | | | | |

5 | adrenal gland renin level | SD | male | 0.5 | ng/ml/h | unilateral nephrectomy (between 12 and 14 days) then enalapril (50 mg/l) (between 12 and 14 days) and losartan (180 mg/l) (between 12 and 14 days) and Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | 101570 | unilateral nephrectomy (between 12 and 14 days) | | | enalapril (50 mg/l) (between 12 and 14 days) | losartan (180 mg/l) (between 12 and 14 days) | Aldosterone (30~40 mg/kg/d) (between 12 and 14 days) | | | |

6 | body weight | SD | male | 347 | g | sham surgical control condition (for 28 days) | 101571 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | body weight | SD | male | 309 | g | unilateral nephrectomy (for 28 days) | 101572 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | body weight | SD | male | 307 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101573 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | body weight | SD | male | 312 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101574 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | change in body weight | SD | male | 99 | g | sham surgical control condition (for 28 days) | 101575 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | change in body weight | SD | male | 96 | g | unilateral nephrectomy (for 28 days) | 101576 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | change in body weight | SD | male | 97 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101577 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | change in body weight | SD | male | 106 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101578 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | left kidney wet weight | SD | male | 1.19 | g | sham surgical control condition (for 28 days) | 101579 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | left kidney wet weight | SD | male | 1.91 | g | unilateral nephrectomy (for 28 days) | 101580 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | left kidney wet weight | SD | male | 1.47 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101581 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | left kidney wet weight | SD | male | 2.03 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101582 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | systolic blood pressure | SD | male | 118 | mmHg | sham surgical control condition (for 28 days) | 101583 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | systolic blood pressure | SD | male | 212 | mmHg | unilateral nephrectomy (for 28 days) | 101584 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | systolic blood pressure | SD | male | 109 | mmHg | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101585 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | systolic blood pressure | SD | male | 186 | mmHg | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101586 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | heart wet weight | SD | male | 1.03 | g | sham surgical control condition (for 28 days) | 101587 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | heart wet weight | SD | male | 1.33 | g | unilateral nephrectomy (for 28 days) | 101588 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | heart wet weight | SD | male | 0.88 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101589 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | heart wet weight | SD | male | 1.28 | g | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101590 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | urine protein excretion rate | SD | male | 19 | mg/d | sham surgical control condition (for 28 days) | 101591 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | urine protein excretion rate | SD | male | 203 | mg/d | unilateral nephrectomy (for 28 days) | 101592 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | urine protein excretion rate | SD | male | 30 | mg/d | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101593 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | urine protein excretion rate | SD | male | 217 | mg/d | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101594 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | plasma potassium level | SD | male | 5 | mmol/l | sham surgical control condition (for 28 days) | 101595 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | plasma potassium level | SD | male | 5 | mmol/l | unilateral nephrectomy (for 28 days) | 101596 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | plasma potassium level | SD | male | 6.2 | mmol/l | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101597 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | plasma potassium level | SD | male | 4.5 | mmol/l | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101598 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | adrenal gland weight | SD | male | 46 | mg | sham surgical control condition (for 28 days) | 101599 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | adrenal gland weight | SD | male | 69 | mg | unilateral nephrectomy (for 28 days) | 101600 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | adrenal gland weight | SD | male | 57 | mg | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101601 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | adrenal gland weight | SD | male | 60 | mg | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101602 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

6 | kidney sclerotic glomeruli count to total glomeruli count ratio | SD | male | 1.9 | % | sham surgical control condition (for 28 days) | 101603 | sham surgical control condition (for 28 days) | | | | | | | | |

7 | kidney sclerotic glomeruli count to total glomeruli count ratio | SD | male | 37.2 | % | unilateral nephrectomy (for 28 days) | 101604 | unilateral nephrectomy (for 28 days) | | | | | | | | |

7 | kidney sclerotic glomeruli count to total glomeruli count ratio | SD | male | 4.7 | % | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) | 101605 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | | | | |

6 | kidney sclerotic glomeruli count to total glomeruli count ratio | SD | male | 25.3 | % | unilateral nephrectomy (for 28 days) then enalapril (50 mg/l) (for 28 days) and losartan (180 mg/l) (for 28 days) and Aldosterone (35 mg/kg/d) (for 28 days) | 101606 | unilateral nephrectomy (for 28 days) | | | enalapril (50 mg/l) (for 28 days) | losartan (180 mg/l) (for 28 days) | Aldosterone (35 mg/kg/d) (for 28 days) | | | |

8 | body weight | SD | male | 315 | g | unilateral nephrectomy (for 28 days) | 101607 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | body weight | SD | male | 300 | g | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101608 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | change in body weight | SD | male | 59 | g | unilateral nephrectomy (for 28 days) | 101609 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | change in body weight | SD | male | 48 | g | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101610 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | food intake rate | SD | male | 19 | g/d | unilateral nephrectomy (for 28 days) | 101611 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | food intake rate | SD | male | 23 | g/d | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101612 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | left kidney wet weight | SD | male | 1.96 | g | unilateral nephrectomy (for 28 days) | 101613 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | left kidney wet weight | SD | male | 1.79 | g | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101614 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | systolic blood pressure | SD | male | 201 | mmHg | unilateral nephrectomy (for 14 days) | 101615 | unilateral nephrectomy (for 14 days) | | | | | | | | |

8 | systolic blood pressure | SD | male | 192 | mmHg | unilateral nephrectomy (for 14 days) then spironolactone (5.56 mg/kg/d) (for 14 days) | 101616 | unilateral nephrectomy (for 14 days) | | | spironolactone (5.56 mg/kg/d) (for 14 days) | | | | | |

8 | systolic blood pressure | SD | male | 208 | mmHg | unilateral nephrectomy (for 28 days) | 101617 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | systolic blood pressure | SD | male | 190 | mmHg | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101618 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | heart wet weight | SD | male | 1.33 | g | unilateral nephrectomy (for 28 days) | 101619 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | heart wet weight | SD | male | 1.12 | g | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101620 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | urine protein excretion rate | SD | male | 201 | mg/d | unilateral nephrectomy (for 14 days) | 101621 | unilateral nephrectomy (for 14 days) | | | | | | | | |

8 | urine protein excretion rate | SD | male | 130 | mg/d | unilateral nephrectomy (for 14 days) then spironolactone (5.56 mg/kg/d) (for 14 days) | 101622 | unilateral nephrectomy (for 14 days) | | | spironolactone (5.56 mg/kg/d) (for 14 days) | | | | | |

8 | urine protein excretion rate | SD | male | 283 | mg/d | unilateral nephrectomy (for 28 days) | 101623 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | urine protein excretion rate | SD | male | 243 | mg/d | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101624 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | plasma potassium level | SD | male | 5.3 | mmol/l | unilateral nephrectomy (for 14 days) | 101625 | unilateral nephrectomy (for 14 days) | | | | | | | | |

8 | plasma potassium level | SD | male | 5.2 | mmol/l | unilateral nephrectomy (for 14 days) then spironolactone (5.56 mg/kg/d) (for 14 days) | 101626 | unilateral nephrectomy (for 14 days) | | | spironolactone (5.56 mg/kg/d) (for 14 days) | | | | | |

8 | adrenal gland weight | SD | male | 71 | mg | unilateral nephrectomy (for 28 days) | 101627 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | adrenal gland weight | SD | male | 73 | mg | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101628 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

8 | kidney sclerotic glomeruli count to total glomeruli count ratio | SD | male | 31 | % | unilateral nephrectomy (for 28 days) | 101629 | unilateral nephrectomy (for 28 days) | | | | | | | | |

8 | kidney sclerotic glomeruli count to total glomeruli count ratio | SD | male | 26 | % | unilateral nephrectomy (for 28 days) then spironolactone (5.56 mg/kg/d) (for 28 days) | 101630 | unilateral nephrectomy (for 28 days) | | | spironolactone (5.56 mg/kg/d) (for 28 days) | | | | | |

1 | systolic blood pressure | SD | male | 117 | mmHg | enalapril (5 ml/kg/d) (for 10 days) | 102814 | enalapril (5 ml/kg/d) (for 10 days) | | | | | | | | |

5 | serum creatinine level | SD | male | 0.3 | mg/dl | left nephrectomy (for 70 days) | 103796 | left nephrectomy (for 70 days) | | | | | | | | |

5 | creatinine clearance | SD | male | 1.4 | ml/min | left nephrectomy (for 70 days) | 103797 | left nephrectomy (for 70 days) | | | | | | | | |

8 | serum immunoglobulin E level | SD | not specified | 0.1 | ug/l | naive control condition | 105406 | naive control condition | | | | | | | | |

4 | serum total immunoglobulin E level | SD | not specified | 0.2 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105407 | vehicle control condition | | | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) |

12 | serum total immunoglobulin E level | SD | not specified | 0.1 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105408 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

12 | serum total immunoglobulin E level | SD | not specified | 0.28 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105409 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

8 | serum interleukin-4 level | SD | not specified | 0.04 | ug/l | naive control condition | 105410 | naive control condition | | | | | | | | |

4 | serum interleukin-4 level | SD | not specified | 0.14 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105411 | vehicle control condition | | | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) |

12 | serum interleukin-4 level | SD | not specified | 0.05 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105412 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

12 | serum interleukin-4 level | SD | not specified | 0.15 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105413 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

8 | serum interleukin-9 level | SD | not specified | 0.08 | ug/l | naive control condition | 105414 | naive control condition | | | | | | | | |

4 | serum interleukin-9 level | SD | not specified | 0.1 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105415 | vehicle control condition | | | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) |

12 | serum interleukin-9 level | SD | not specified | 0.08 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105416 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

12 | serum interleukin-9 level | SD | not specified | 0.21 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105417 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

8 | intestine trypsin level | SD | not specified | 0.08 | ug/l | naive control condition | 105418 | naive control condition | | | | | | | | |

4 | intestine trypsin level | SD | not specified | 0.17 | ug/l | vehicle control condition then acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105419 | vehicle control condition | | | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | fasting (for 1 days) |

12 | intestine trypsin level | SD | not specified | 0.11 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105420 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

12 | intestine trypsin level | SD | not specified | 0.23 | ug/l | acetic acid (for 0 hours) then physical restraint in tube type rodent restrainer (for 2 hours) then fasting (for 1 days) | 105421 | acetic acid (for 0 hours) | | | physical restraint in tube type rodent restrainer (for 2 hours) | | | fasting (for 1 days) | | |

6 | elimination half life of nifedipine in the plasma | SD | both | 35.52 | min | nifedipine (200 ug/kg) | 105706 | nifedipine (200 ug/kg) | | | | | | | | |

6 | blood nifedipine level | SD | both | 926.52 | ng/ml | nifedipine (200 ug/kg) | 105708 | nifedipine (200 ug/kg) | | | | | | | | |

6 | the first 120min of plasma nifedipine level area under curve | SD | both | 26979.23 | min x (ng/ml) | nifedipine (200 ug/kg) | 105710 | nifedipine (200 ug/kg) | | | | | | | | |

6 | plasma nifedipine level area under curve | SD | both | 30118.55 | min x (ng/ml) | nifedipine (200 ug/kg) | 105712 | nifedipine (200 ug/kg) | | | | | | | | |

6 | volume of distribution of nifedipine in the blood | SD | both | 341.11 | ml/kg | nifedipine (200 ug/kg) | 105714 | nifedipine (200 ug/kg) | | | | | | | | |

6 | plasma nifedipine clearance | SD | both | 6.67 | ml/min/kg | nifedipine (200 ug/kg) | 105716 | nifedipine (200 ug/kg) | | | | | | | | |

6 | nifedipine mean residence time | SD | both | 38.06 | min | nifedipine (200 ug/kg) | 105718 | nifedipine (200 ug/kg) | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 3.647 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105720 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 3.647 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105721 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 4.157 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105722 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 4.689 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105723 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 5.028 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105724 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | liver weight as percentage of body weight | SD | female | 5.074 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105725 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 1.5 | mg/g | vehicle control condition (5 ml/kg) (for 28 days) | 105884 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 1.47 | mg/g | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105886 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 1.49 | mg/g | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105888 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 1.29 | mg/g | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105890 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 1.03 | mg/g | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105892 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | thymus weight to body weight ratio | SD | female | 0.65 | mg/g | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105894 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.299 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105896 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.287 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105898 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.28 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105900 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.278 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105902 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.278 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105904 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | spleen weight to body weight ratio | SD | female | 0.265 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105906 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.742 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105908 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.757 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105910 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.753 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105912 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.768 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105914 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.756 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105916 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | brain weight to body weight ratio | SD | female | 0.836 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105918 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.049 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105920 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.046 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105922 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.054 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105924 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.043 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105926 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.041 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105928 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | both ovaries weight to body weight ratio | SD | female | 0.037 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105930 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | red blood cell count | SD | female | 7.47 | x 10E6 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 105932 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | red blood cell count | SD | female | 7.63 | x 10E6 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105934 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | red blood cell count | SD | female | 7.68 | x 10E6 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105936 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | red blood cell count | SD | female | 8.02 | x 10E6 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105938 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | red blood cell count | SD | female | 8.21 | x 10E6 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105940 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | red blood cell count | SD | female | 9.17 | x 10E6 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105942 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.17775 | mmol/l | vehicle control condition (5 ml/kg) (for 28 days) | 105944 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.2165 | mmol/l | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105946 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.21185 | mmol/l | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105948 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.26145 | mmol/l | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105950 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.2754 | mmol/l | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105952 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hemoglobin concentration | SD | female | 2.4428 | mmol/l | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105954 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hematocrit | SD | female | 43.31 | % | vehicle control condition (5 ml/kg) (for 28 days) | 105956 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | hematocrit | SD | female | 44.34 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105958 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hematocrit | SD | female | 44.42 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105960 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hematocrit | SD | female | 45.1 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105962 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hematocrit | SD | female | 44.79 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105964 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | hematocrit | SD | female | 48.55 | % | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105966 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular volume | SD | female | 57.96 | fl | vehicle control condition (5 ml/kg) (for 28 days) | 105968 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | mean corpuscular volume | SD | female | 58.08 | fl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105970 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular volume | SD | female | 57.82 | fl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105972 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular volume | SD | female | 56.27 | fl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105974 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular volume | SD | female | 54.57 | fl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105976 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular volume | SD | female | 52.98 | fl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105978 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 18.82 | pg | vehicle control condition (5 ml/kg) (for 28 days) | 105980 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 18.71 | pg | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105982 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 18.61 | pg | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105984 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 18.19 | pg | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105986 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 17.89 | pg | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 105988 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin level | SD | female | 17.22 | pg | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 105990 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.48 | g/dl | vehicle control condition (5 ml/kg) (for 28 days) | 105992 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.23 | g/dl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 105994 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.17 | g/dl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 105996 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.37 | g/dl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 105998 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.81 | g/dl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106000 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | mean corpuscular hemoglobin concentration | SD | female | 32.51 | g/dl | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106002 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | platelet count | SD | female | 1308.4 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106004 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | platelet count | SD | female | 1291.9 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106006 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | platelet count | SD | female | 1299.4 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106008 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | platelet count | SD | female | 1280.89 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106010 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | platelet count | SD | female | 1160.6 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106012 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | platelet count | SD | female | 870.2 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106014 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | white blood cell count | SD | female | 9.42 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106016 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | white blood cell count | SD | female | 10.39 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106018 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | white blood cell count | SD | female | 9.63 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106020 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | white blood cell count | SD | female | 9.64 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106022 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | white blood cell count | SD | female | 10.54 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106024 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | white blood cell count | SD | female | 8.73 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106026 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.48 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106028 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.86 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106030 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.38 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106032 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.16 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106034 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.62 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106036 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood neutrophil count | SD | female | 1.08 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106038 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood lymphocyte count | SD | female | 7.36 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106040 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | blood lymphocyte count | SD | female | 7.88 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106042 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood lymphocyte count | SD | female | 7.73 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106044 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood lymphocyte count | SD | female | 7.97 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106046 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood lymphocyte count | SD | female | 8.36 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106048 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood lymphocyte count | SD | female | 7.18 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106050 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood monocyte count | SD | female | 0.29 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106052 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | blood monocyte count | SD | female | 0.33 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106054 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood monocyte count | SD | female | 0.29 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106056 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood monocyte count | SD | female | 0.27 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106058 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood monocyte count | SD | female | 0.32 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106060 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood monocyte count | SD | female | 0.24 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106062 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.13 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106064 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.16 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106066 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.08 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106068 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.07 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106070 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.04 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106072 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood eosinophil count | SD | female | 0.04 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106074 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood basophil count | SD | female | 0.07 | x 1000 cells/ul | vehicle control condition (5 ml/kg) (for 28 days) | 106076 | vehicle control condition (5 ml/kg) (for 28 days) | | | | | | | | |

10 | blood basophil count | SD | female | 0.08 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | 106078 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (3 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood basophil count | SD | female | 0.08 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | 106080 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (22 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood basophil count | SD | female | 0.08 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | 106082 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (100 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood basophil count | SD | female | 0.1 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | 106084 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (300 ng/kg/d) (for 28 days) | | | | | | | | |

10 | blood basophil count | SD | female | 0.08 | x 1000 cells/ul | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | 106086 | 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1000 ng/kg/d) (for 28 days) | | | | | | | | |

3 | verapamil apparent influx permeability clearance in retina barrier | SD | male | 0.824 | ml/min/g | tritiated verapamil (10 uCi) (for 0 hours) | 106102 | tritiated verapamil (10 uCi) (for 0 hours) | | | | | | | | |

3 | verapamil apparent influx permeability clearance in aqueous humor | SD | male | 0.0022 | ml/min/g | tritiated verapamil (10 uCi) (for 0 hours) | 106103 | tritiated verapamil (10 uCi) (for 0 hours) | | | | | | | | |

3 | verapamil equilibrated distribution volume in retina | SD | male | 3.32 | ml/g | tritiated verapamil (10 uCi) (for 0 hours) | 106108 | tritiated verapamil (10 uCi) (for 0 hours) | | | | | | | | |

3 | verapamil equilibrated distribution volume in aqueous humor | SD | male | 0.0728 | ml/g | tritiated verapamil (10 uCi) (for 0 hours) | 106109 | tritiated verapamil (10 uCi) (for 0 hours) | | | | | | | | |

3 | verapamil equilibrated distribution volume in brain | SD | male | 0.542 | ml/g | tritiated verapamil (10 uCi) (for 0 hours) | 106110 | tritiated verapamil (10 uCi) (for 0 hours) | | | | | | | | |

3 | quinidine uptake index in retina | SD | male | 212 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106114 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | quinidine uptake index in retina | SD | male | 187 | % | tritiated quinidine (10 uCi) (for 0 hours) and quinidine (10 mmol/l) (for 0 hours) | 106115 | tritiated quinidine (10 uCi) (for 0 hours) | quinidine (10 mmol/l) (for 0 hours) | | | | | | | |

3 | quinidine uptake index in retina | SD | male | 180 | % | tritiated quinidine (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106116 | tritiated quinidine (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in retina | SD | male | 24 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106117 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | digoxin uptake index in retina | SD | male | 26.3 | % | tritiated digoxin (10 uCi) (for 0 hours) and digoxin (0.01 mmol/l) (for 0 hours) | 106118 | tritiated digoxin (10 uCi) (for 0 hours) | digoxin (0.01 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in retina | SD | male | 27.9 | % | tritiated digoxin (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106119 | tritiated digoxin (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | verapamil uptake index in retina | SD | male | 336 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106120 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | verapamil uptake index in retina | SD | male | 327 | % | tritiated verapamil (10 uCi) (for 0 hours) and vinblastine (1 mmol/l) (for 0 hours) | 106121 | tritiated verapamil (10 uCi) (for 0 hours) | vinblastine (1 mmol/l) (for 0 hours) | | | | | | | |

3 | verapamil uptake index in retina | SD | male | 439 | % | tritiated verapamil (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106122 | tritiated verapamil (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | quinidine uptake index in aqueous humor | SD | male | 5.95 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106132 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | quinidine uptake index in aqueous humor | SD | male | 11.7 | % | tritiated quinidine (10 uCi) (for 0 hours) and quinidine (10 mmol/l) (for 0 hours) | 106133 | tritiated quinidine (10 uCi) (for 0 hours) | quinidine (10 mmol/l) (for 0 hours) | | | | | | | |

3 | quinidine uptake index in aqueous humor | SD | male | 14.2 | % | tritiated quinidine (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106134 | tritiated quinidine (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in aqueous humor | SD | male | 17.5 | % | tritiated quinidine (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106135 | tritiated quinidine (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in aqueous humor | SD | male | 15.8 | % | tritiated digoxin (10 uCi) (for 0 hours) and digoxin (0.01 mmol/l) (for 0 hours) | 106136 | tritiated digoxin (10 uCi) (for 0 hours) | digoxin (0.01 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in aqueous humor | SD | male | 9.48 | % | tritiated digoxin (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106137 | tritiated digoxin (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | verapamil uptake index in aqueous humor | SD | male | 8.46 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106138 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | verapamil uptake index in aqueous humor | SD | male | 15.7 | % | tritiated verapamil (10 uCi) (for 0 hours) and vinblastine (1 mmol/l) (for 0 hours) | 106139 | tritiated verapamil (10 uCi) (for 0 hours) | vinblastine (1 mmol/l) (for 0 hours) | | | | | | | |

3 | verapamil uptake index in aqueous humor | SD | male | 23.1 | % | tritiated verapamil (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106140 | tritiated verapamil (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | quinidine uptake index in brain | SD | male | 2.12 | % | tritiated quinidine (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106150 | tritiated quinidine (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | quinidine uptake index in brain | SD | male | 18.2 | % | tritiated quinidine (10 uCi) (for 0 hours) and quinidine (10 mmol/l) (for 0 hours) | 106151 | tritiated quinidine (10 uCi) (for 0 hours) | quinidine (10 mmol/l) (for 0 hours) | | | | | | | |

3 | quinidine uptake index in brain | SD | male | 13.2 | % | tritiated quinidine (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106152 | tritiated quinidine (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in brain | SD | male | 0.987 | % | tritiated digoxin (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106153 | tritiated digoxin (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | digoxin uptake index in brain | SD | male | 1.18 | % | tritiated digoxin (10 uCi) (for 0 hours) and digoxin (0.01 mmol/l) (for 0 hours) | 106154 | tritiated digoxin (10 uCi) (for 0 hours) | digoxin (0.01 mmol/l) (for 0 hours) | | | | | | | |

3 | digoxin uptake index in brain | SD | male | 0.96 | % | tritiated digoxin (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106155 | tritiated digoxin (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

3 | verapamil uptake index in brain | SD | male | 9.07 | % | tritiated verapamil (10 uCi) (for 0 hours) and vehicle control condition (for 0 hours) | 106156 | tritiated verapamil (10 uCi) (for 0 hours) | vehicle control condition (for 0 hours) | | | | | | | |

3 | verapamil uptake index in brain | SD | male | 42.5 | % | tritiated verapamil (10 uCi) (for 0 hours) and vinblastine (1 mmol/l) (for 0 hours) | 106157 | tritiated verapamil (10 uCi) (for 0 hours) | vinblastine (1 mmol/l) (for 0 hours) | | | | | | | |

3 | verapamil uptake index in brain | SD | male | 77.7 | % | tritiated verapamil (10 uCi) (for 0 hours) and verapamil (3 mmol/l) (for 0 hours) | 106158 | tritiated verapamil (10 uCi) (for 0 hours) | verapamil (3 mmol/l) (for 0 hours) | | | | | | | |

5 | serum alanine aminotransferase activity level | SD | male | 56.6 | U/l | naive control condition (for 84 days) | 106362 | naive control condition (for 84 days) | | | | | | | | |

5 | serum alanine aminotransferase activity level | SD | female | 65 | U/l | naive control condition (for 84 days) | 106364 | naive control condition (for 84 days) | | | | | | | | |

5 | serum aspartate aminotransferase activity level | SD | male | 156.2 | U/l | naive control condition (for 84 days) | 106366 | naive control condition (for 84 days) | | | | | | | | |

5 | serum aspartate aminotransferase activity level | SD | female | 134.2 | U/l | naive control condition (for 84 days) | 106368 | naive control condition (for 84 days) | | | | | | | | |

5 | serum alkaline phosphatase activity level | SD | male | 74.6 | U/l | naive control condition (for 84 days) | 106370 | naive control condition (for 84 days) | | | | | | | | |

5 | serum alkaline phosphatase activity level | SD | female | 77 | U/l | naive control condition (for 84 days) | 106372 | naive control condition (for 84 days) | | | | | | | | |

5 | total serum bilirubin level | SD | male | 0.05 | mg/dl | naive control condition (for 84 days) | 106374 | naive control condition (for 84 days) | | | | | | | | |

5 | total serum bilirubin level | SD | female | 0.05 | mg/dl | naive control condition (for 84 days) | 106376 | naive control condition (for 84 days) | | | | | | | | |

5 | serum total protein level | SD | male | 70 | g/dl | naive control condition (for 84 days) | 106382 | naive control condition (for 84 days) | | | | | | | | |

5 | serum total protein level | SD | female | 67 | g/dl | naive control condition (for 84 days) | 106384 | naive control condition (for 84 days) | | | | | | | | |

5 | serum albumin level | SD | male | 4.5 | g/dl | naive control condition (for 84 days) | 106386 | naive control condition (for 84 days) | | | | | | | | |

5 | serum albumin level | SD | female | 4.5 | g/dl | naive control condition (for 84 days) | 106388 | naive control condition (for 84 days) | | | | | | | | |

5 | serum globulin level | SD | male | 2.5 | g/dl | naive control condition (for 84 days) | 106390 | naive control condition (for 84 days) | | | | | | | | |

5 | serum globulin level | SD | female | 2.2 | g/dl | naive control condition (for 84 days) | 106392 | naive control condition (for 84 days) | | | | | | | | |

5 | blood albumin level to blood globulin level ratio | SD | male | 1.8 | | naive control condition (for 84 days) | 106394 | naive control condition (for 84 days) | | | | | | | | |

5 | blood albumin level to blood globulin level ratio | SD | female | 2.1 | | naive control condition (for 84 days) | 106396 | naive control condition (for 84 days) | | | | | | | | |

5 | serum total cholesterol level | SD | male | 113.8 | mg/dl | naive control condition (for 84 days) | 106398 | naive control condition (for 84 days) | | | | | | | | |

5 | serum total cholesterol level | SD | female | 106.8 | mg/dl | naive control condition (for 84 days) | 106400 | naive control condition (for 84 days) | | | | | | | | |

5 | serum triglyceride level | SD | male | 156.8 | mg/dl | naive control condition (for 84 days) | 106402 | naive control condition (for 84 days) | | | | | | | | |

5 | serum triglyceride level | SD | female | 130.4 | mg/dl | naive control condition (for 84 days) | 106404 | naive control condition (for 84 days) | | | | | | | | |

5 | serum urea nitrogen level | SD | male | 22.4 | mg/dl | naive control condition (for 84 days) | 106406 | naive control condition (for 84 days) | | | | | | | | |

5 | serum urea nitrogen level | SD | female | 24.6 | mg/dl | naive control condition (for 84 days) | 106408 | naive control condition (for 84 days) | | | | | | | | |

5 | serum creatinine level | SD | male | 0.3 | mg/dl | naive control condition (for 84 days) | 106410 | naive control condition (for 84 days) | | | | | | | | |

5 | serum creatinine level | SD | female | 0.34 | mg/dl | naive control condition (for 84 days) | 106412 | naive control condition (for 84 days) | | | | | | | | |

5 | serum glucose level | SD | male | 285 | mg/dl | naive control condition (for 84 days) | 106414 | naive control condition (for 84 days) | | | | | | | | |

5 | serum glucose level | SD | female | 311.2 | mg/dl | naive control condition (for 84 days) | 106416 | naive control condition (for 84 days) | | | | | | | | |

5 | serum sodium level | SD | male | 149.4 | mmol/l | naive control condition (for 84 days) | 106418 | naive control condition (for 84 days) | | | | | | | | |

5 | serum sodium level | SD | female | 149 | mmol/l | naive control condition (for 84 days) | 106420 | naive control condition (for 84 days) | | | | | | | | |

5 | serum chloride level | SD | male | 100.2 | mmol/l | naive control condition (for 84 days) | 106426 | naive control condition (for 84 days) | | | | | | | | |

5 | serum chloride level | SD | female | 100.4 | mmol/l | naive control condition (for 84 days) | 106428 | naive control condition (for 84 days) | | | | | | | | |

5 | serum calcium level | SD | male | 13.2 | mg/dl | naive control condition (for 84 days) | 106430 | naive control condition (for 84 days) | | | | | | | | |

5 | serum calcium level | SD | female | 13.9 | mg/dl | naive control condition (for 84 days) | 106432 | naive control condition (for 84 days) | | | | | | | | |

5 | serum phosphate level | SD | male | 12.3 | mg/dl | naive control condition (for 84 days) | 106434 | naive control condition (for 84 days) | | | | | | | | |

5 | serum phosphate level | SD | female | 12.6 | mg/dl | naive control condition (for 84 days) | 106436 | naive control condition (for 84 days) | | | | | | | | |

5 | body weight | SD | male | 386.2 | g | naive control condition (for 84 days) | 106438 | naive control condition (for 84 days) | | | | | | | | |

5 | body weight | SD | female | 257.6 | g | naive control condition (for 84 days) | 106440 | naive control condition (for 84 days) | | | | | | | | |

5 | liver weight | SD | male | 4.61 | g | naive control condition (for 84 days) | 106442 | naive control condition (for 84 days) | | | | | | | | |

5 | liver weight | SD | female | 4.35 | g | naive control condition (for 84 days) | 106444 | naive control condition (for 84 days) | | | | | | | | |

5 | kidney weight | SD | male | 0.88 | g | naive control condition (for 84 days) | 106446 | naive control condition (for 84 days) | | | | | | | | |

5 | kidney weight | SD | female | 0.81 | g | naive control condition (for 84 days) | 106448 | naive control condition (for 84 days) | | | | | | | | |

5 | heart weight | SD | male | 0.38 | g | naive control condition (for 84 days) | 106450 | naive control condition (for 84 days) | | | | | | | | |

5 | heart weight | SD | female | 0.39 | g | naive control condition (for 84 days) | 106452 | naive control condition (for 84 days) | | | | | | | | |

5 | pancreas weight | SD | male | 280 | mg | naive control condition (for 84 days) | 106454 | naive control condition (for 84 days) | | | | | | | | |

5 | pancreas weight | SD | female | 390 | mg | naive control condition (for 84 days) | 106456 | naive control condition (for 84 days) | | | | | | | | |

5 | spleen weight | SD | male | 0.25 | g | naive control condition (for 84 days) | 106458 | naive control condition (for 84 days) | | | | | | | | |

5 | spleen weight | SD | female | 0.3 | g | naive control condition (for 84 days) | 106460 | naive control condition (for 84 days) | | | | | | | | |

5 | thymus weight | SD | male | 0.16 | g | naive control condition (for 84 days) | 106462 | naive control condition (for 84 days) | | | | | | | | |

5 | thymus weight | SD | female | 0.15 | g | naive control condition (for 84 days) | 106464 | naive control condition (for 84 days) | | | | | | | | |

5 | brain weight | SD | male | 0.48 | g | naive control condition (for 84 days) | 106466 | naive control condition (for 84 days) | | | | | | | | |

5 | brain weight | SD | female | 0.67 | g | naive control condition (for 84 days) | 106468 | naive control condition (for 84 days) | | | | | | | | |

5 | lung weight | SD | male | 0.59 | g | naive control condition (for 84 days) | 106470 | naive control condition (for 84 days) | | | | | | | | |

5 | lung weight | SD | female | 0.73 | g | naive control condition (for 84 days) | 106472 | naive control condition (for 84 days) | | | | | | | | |

5 | thyroid gland weight | SD | male | 0.006 | g | naive control condition (for 84 days) | 106474 | naive control condition (for 84 days) | | | | | | | | |

5 | thyroid gland weight | SD | female | 0.008 | g | naive control condition (for 84 days) | 106476 | naive control condition (for 84 days) | | | | | | | | |

5 | adrenal gland weight | SD | male | 13 | mg | naive control condition (for 84 days) | 106478 | naive control condition (for 84 days) | | | | | | | | |

5 | adrenal gland weight | SD | female | 26 | mg | naive control condition (for 84 days) | 106480 | naive control condition (for 84 days) | | | | | | | | |

5 | pituitary gland weight | SD | male | 0.004 | g | naive control condition (for 84 days) | 106482 | naive control condition (for 84 days) | | | | | | | | |

5 | pituitary gland weight | SD | female | 0.006 | g | naive control condition (for 84 days) | 106484 | naive control condition (for 84 days) | | | | | | | | |

12 | both ovaries weight | SD | female | 0.048 | g | naive control condition (for 84 days) | 106486 | naive control condition (for 84 days) | | | | | | | | |

12 | both testes wet weight | SD | male | 0.99 | g | naive control condition (for 84 days) | 106488 | naive control condition (for 84 days) | | | | | | | | |

12 | epididymides weight | SD | male | 0.56 | g | naive control condition (for 84 days) | 106490 | naive control condition (for 84 days) | | | | | | | | |

12 | prostate gland weight | SD | male | 0.25 | g | naive control condition (for 84 days) | 106492 | naive control condition (for 84 days) | | | | | | | | |